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Bacterial infections in dogs with special reference to urinary tract 
infections, surgical site infections and methicillin-resistant 
Staphylococcus pseudintermedius 
Abstract 
An increase in antimicrobial resistance in canine bacterial pathogens, including 
multidrug-resistance, has been reported worldwide. Increasing antimicrobial 
resistance is of concern, not only as it complicates therapy in dogs, but also as 
it is a public health problem when the pathogens are zoonotic, or the location 
of resistance genes enables transfer between bacteria of animal and human 
origin.  
The overall aims of this thesis were to gain knowledge of bacterial 
infections in dogs with special reference to urinary tract infections (UTI), 
surgical site infections (SSI) and their antimicrobial susceptibility patterns, and 
of carriage of methicillin-resistant Staphylococcus pseudintermedius (MRSP). 
The results were intended to aid in choice of antimicrobial treatment of canine 
UTI and SSI, and in designing recommendations on prevention and control of 
carriage of MRSP. 
First-line antimicrobials were found to be a rational empirical antimicrobial 
therapy for the studied dog population. In total three percent of detected 
Escherichia coli isolates were resistant to extended-spectrum cephalosporins. 
Less than 3% of Staphylococcus pseudintermedius isolates were methicillin 
resistant. No methicillin-resistant Staphylococcus aureus (MRSA) isolates 
were found.  
Dogs carried MRSP for several months without clinical signs. Systemic 
treatment for three weeks or longer with antimicrobials to which the bacterium 
was resistant was associated with prolonged carriage compared to shorter 
treatment periods. Three of five dogs treated with an antimicrobial to which the 
MRSP isolates were susceptible remained MRSP carriers. These findings 
support restricted use of systemic antimicrobial treatment in dogs with possible 
or confirmed MRSP carriage or infection. The risk of MRSP colonization in 
dogs living in a household with an MRSP infected dog might be lowered if the 
clinically infected dog (index dog) becomes MRSP negative. Furthermore, all 
contact dogs in the family might not carry MRSP continuously during the time 
the index dog is MRSP positive. The results of the evaluation of five body sites 
for MRSP carriage screening suggest that simultaneous sampling of pharynx, 
perineum and the corner of the mouth, as well as wounds when present, should 
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be recommended. Furthermore, the results suggest that sampling of nostrils is 
not a priority when screening dogs for MRSP. 
Keywords: bacterial infections, dogs, canine, urinary, surgical, 
antimicrobial resistance methicillin-resistant Staphylococcus pseudintermedius 
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1 Background 
 
Bacterial infections can cause severe morbidity and mortality in dogs, as well 
as in other animals, and humans. The development of antimicrobials has 
therefore had a profound positive impact on human and animal health and 
thereby welfare. Prompt antimicrobial therapy for an infected veterinary 
patient can make the difference between cure and death or long-term disability. 
Antimicrobial therapy has also allowed for various medical and surgical 
advances in the veterinary field, as well as in the human field for more than 50 
years (WHO, 2014b, Lloyd, 2010, Weese, 2008a, Guardabassi and Prescott, 
2015, Weese et al., 2015, WHO, 2014a). In human medicine, a well-
documented rapid increase in antimicrobial resistance has been labelled a 
severe threat to global health by the world health organization (WHO) (WHO, 
2014a, WHO, 2014b). 
An increase in prevalence of antimicrobial resistance including multidrug 
resistance (MDR) has during the last two decades been reported in different 
bacterial species isolated from dogs worldwide (Wieler LH, 2011, Ewers et al., 
2011, Pellerin et al., 1998, Prescott et al., 2002, van Duijkeren et al., 2011a, 
Guardabassi et al., 2004b). Canine antimicrobial resistant bacterial infections 
can increase morbidity, mortality and prolong hospitalization for the dogs. The 
infections can also lead to increased treatment cost and emotional strain on the 
pet owner. In addition to complicating therapy in dogs, increasing 
antimicrobial resistance in canine pathogens is also of public health concern 
when the pathogens are zoonotic, or the location of resistance genes enables 
transfer between bacteria of animal and human origin (Wieler et al., 2011a, 
Ewers et al., 2012, Weese, 2008a, Guardabassi et al., 2004b). 
Several challenges are involved for the attending veterinarian, including 
assessment of possible health implications for persons involved and which 
rational antimicrobial treatment strategies to choose. The reports on emerging 
antimicrobial resistance in important canine pathogens can per se put pressure 
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on clinically active veterinarians to use antimicrobials other than traditional 
first-line antimicrobials, including agents of utmost importance for human 
medicine, where they are intended to be used only a last resort choice 
(Guardabassi et al., 2004b, Weese, 2008a, Guardabassi and Prescott, 2015, 
Wieler LH, 2011, Lloyd, 2010). 
Highly resistant bacteria of special concern due to their zoonotic potential 
include Enterobacteriaceae resistant to extended-spectrum cephalosporins 
(ESC), and methicillin-resistant Staphylococcus aureus (MRSA). Clones of 
these bacteria, that are resistant to beta-lactam antimicrobials, the most 
important, and widely used antimicrobial class in both humans and dogs, have 
emerged as a significant problem in human healthcare worldwide. In addition, 
MRSA clones and Enterobacteriaceae resistant to other antimicrobial classes as 
well are an increasing threat in human medicine. The rapid worldwide spread 
of these pathogens where treatment options often are severely limited make 
them prime examples of why antimicrobial resistance has been declared a 
severe threat to global human health (Guardabassi et al., 2004b, Weese and van 
Duijkeren, 2010, Wieler et al., 2011b, WHO, 2014a).  
Escherichia coli (E. coli) and other bacteria belonging to the family 
Enterobactericeae are ubiquitous colonizers of the gut flora and important 
pathogens in dogs and other companion animals. Transmission of the 
antimicrobial resistance genes encoding for ESC resistance can spread between 
bacteria of the same, or different, species. As the gut flora contains kilograms 
of bacteria that can exchange such resistance genes, the gut can act as a 
reservoir for antimicrobial resistance genes (Brolund, 2014, Wieler LH, 2011). 
An increase in detection of Enterobacteriaceae isolates with transferable genes 
conferring ESC resistance from dogs is reported worldwide. Clinical infections 
have also been described (Rubin and Pitout, 2014, Wieler LH, 2011, 
Guardabassi et al., 2004b, Ewers et al., 2012). Neither the true prevalence in 
dogs nor the zoonotic risk is well described (Rubin and Pitout, 2014). A few 
studies have indicated that exposure to companion animals might be a risk 
factor for ESBL carriage in humans, e.g. (Leistner et al., 2013, Meyer et al., 
2012, Ewers et al., 2012).  
Prevalence of Enterobacteriaceae with ESC-resistance is thought to be low 
in Swedish dogs, as few positive samples are submitted. At the National 
veterinary Institute, 60 isolates of Enterobacteriaceae with genes conferring 
ESBL- or AmpC-production were confirmed in dogs and cats in the period 
2008 to 2013 (SWEDRES-SVARM, 2013). 
MRSA has been labelled a bacterial pathogen of particular international 
public health concern by the WHO (WHO, 2014a). Humans are natural 
reservoirs for S. aureus, and asymptomatic colonization is far more common 
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than infection (Chambers, 2001). Canine infection with MRSA has primarily 
been reported since the late 1990s. Carriage and infection in dogs has since 
been reported worldwide, including primarily surgical site infections, wound, 
skin and soft tissue infections (Loeffler and Lloyd, 2010, Weese, 2008c). So 
far, MRSA seems to be a relatively uncommon pathogen in dogs, but the 
multidrug resistance and the zoonotic implications makes MRSA an important 
small animal veterinary pathogen (Loeffler and Lloyd, 2010, Weese, 2008c, 
Guardabassi, 2013). MRSA strains isolated from dogs and cats have mostly 
been identical to the MRSA lineages prevalent in human health care in 
respective geographical region, and carriage appears to be more widespread in 
areas where MRSA is commonly detected in humans (Loeffler and Lloyd, 
2010). Although carriage in dogs has been suggested to be short lived when the 
individual dog is not continuously exposed to MRSA, the possible role of dogs 
as reservoirs for MRSA in humans is unclear (Loeffler and Lloyd, 2010). 
MRSA positive dogs may still play an important role as reservoirs within 
family households (Guardabassi et al., 2004b, Hanselman et al., 2009). 
Furthermore, higher rates of MRSA carriage in veterinary staff compared to 
healthy community members have also been reported (Loeffler and Lloyd, 
2010).  MRSA in dogs could therefore be an occupational risk, as carriers have 
a higher risk of acquiring an MRSA infection. Conversely, MRSA colonized 
veterinary personnel might act as sources for MRSA infection in veterinary 
patients (Weese, 2008a).  
Compared to international data, the prevalence of MRSA in Sweden is low 
both in humans and in animals. MRSA in animals is notifiable since 2008. The 
first canine MRSA isolate was detected in 2006. Since then less than 30 
isolates have been reported according to  the Swedish Board of Agriculture 
(www.jordbruksverket.se) (SVARM, 2010, SWEDRES-SVARM, 2013). 
Methicillin-resistant Staphylococcus pseudintermedius (MRSP) is a 
multidrug resistant canine pathogen that - albeit with zoonotic potential, as 
infections and carriage in humans is reported - during the last decade has 
emerged as a major challenge mainly for small animal veterinarians (van 
Duijkeren et al., 2011a, Frank and Loeffler, 2012). 
 
1.1.1 Health care associated infections 
Receiving care in a hospital or in other health care facilities can in itself 
increase the risk for acquiring antimicrobial resistant infections. Health care 
associated infections (HAI), also called nosocomial infections, are infections 
caused by bacteria or other infectious organisms that are acquired by the 
patient during hospitalization. It was previously thought that nosocomial 
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infections originated from bacteria that were part of the endogenous flora of 
the patient, but more recent studies have shown that many HAI are caused by 
organisms acquired from the hospital environment (Johnson, 2002, Ducel et 
al.). A HAI definition used by WHO is: “An infection occurring in a patient in 
a hospital or other health care facility in whom the infection was not present or 
incubating at the time of admission. This includes infections acquired in the 
hospital but appearing after discharge, and also occupational infections 
among staff of the facility” (WHO, 2002). Health care-associated infections are 
one of the leading causes of death in human patients, as well as a significant 
burden both for the patient and for public health, and as the economic costs are 
considerable (Ducel et al., Reed and Kemmerly, 2009). 
The selective effects of antimicrobial drug usage and the spread of resistant 
clones and resistance genes in a hospital setting leading to increased 
antimicrobial resistance has for a long time been a well-recognized problem in 
human medicine. Some patient groups, including surgical patients and 
immunocompromised individuals, as well as some care environments such as 
intensive care units are associated with an especially high risk of acquisition of 
nosocomial infections (WHO, 2002). The risk of dogs acquiring an 
antimicrobial resistant bacterial infection spread throughout a veterinary 
healthcare environment (e.g. clinic or hospital) is by now also well recognized 
in small animal medicine. HAI are increasingly complicated by the emergence 
of MDR pathogens both in human and small animal veterinary medicine 
(Wieler et al., 2011b, Guardabassi, 2012, Johnson, 2002, Weese and van 
Duijkeren, 2010, Frank and Loeffler, 2012, Weese, 2012). Enterobacteriaceae 
resistant to ESC and MRSA are among the most important causes of HAI in 
human medicine. As colonized and infected patients becomes more prevalent 
in the community, the risk of community-acquired infections with infections 
which were initially acquired almost exclusively as HAI infections (HA-
MRSA) increases. Presently, some MRSA clones are instead primarily 
community-associated (CA-MRSA). Such clones can also enter the healthcare 
environment and infect patients (Chambers, 2001, Lawes et al., 2015, Egea et 
al., 2014, Guardabassi, 2012). MRSA is also recognized as a nosocomial 
pathogen in dogs (Wieler et al., 2011b, Vincze et al., 2014, Loeffler and Lloyd, 
2010).  
Sources of infection include the physical environment, bacteria on hands 
and clothes of personnel, carriage o staphylococci in the nasal passages of the 
staff, and surgical equipment. Nosocomial pathogens have been shown to 
persist in the hospital environment in a variety of locations and bacterial 
colonization of human hospital patients by endemic hospital organisms has 
been shown to occur in patients within a few days of hospitalization (Johnson, 
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2002, Glickman, 1981, Hamilton et al., 2013, Nelson, 2011, Guardabassi, 
2012, Weese and van Duijkeren, 2010, Murphy et al., 2010, Ishihara et al., 
2010, Ducel et al.).  
The critical role of infection control in veterinary healthcare environments 
in preventing the spread of multidrug resistant bacteria in small animals has 
been highlighted (Wieler et al., 2011b, Guardabassi, 2012, Johnson, 2002, 
Weese and van Duijkeren, 2010, Frank and Loeffler, 2012, Weese, 2012). 
Some basic infection control guidelines for small animal veterinary medicine 
are readily available, e.g. those developed by the British Small Animal 
Veterinary Association (www.bsava.com) and the Federation of European 
Companion Animal Veterinary Associations (www.fecava.org). 
 
1.1.2 Antimicrobial use and antimicrobial susceptibility testing  
Misuse and overuse of antimicrobials are recognized as key drivers in 
antimicrobial resistance in human medicine and the consequences of 
antimicrobial use in veterinary practice cannot be expected to be different. Any 
use of antimicrobials, whether considered therapeutic or not, and prudent or 
otherwise, exposes bacterial pathogens and the commensal microbiota to 
varying concentrations of antimicrobial drug for variable times. This creates a 
selection pressure that can result in emergence of resistance or, if a resistant 
subpopulation is present, an increase in the abundance of resistant bacteria  
(WHO, 2014b, Guardabassi et al., 2004b, Weese et al., 2015, Johnson, 2002, 
Ogeer-Gyles et al., 2006b, Guardabassi and Prescott, 2015, Prescott et al., 
2002).  
The development of new antimicrobial drugs has over the past decades been 
slow, and bacteria are capable to develop a wide range of resistance 
mechanisms. The need to use the relatively few antimicrobials available 
wisely, and to slow down the current rate of antimicrobial resistance 
development and spread has been increasingly recognized in small animal and 
human medicine (Gould, 2009, Guardabassi and Prescott, 2015, Weese, 2008a, 
Lloyd, 2010).  
As antimicrobial resistance increases, treatment of bacterial infections 
according to past clinical experience (i.e. empirical therapy) is becoming more 
difficult. Unnecessary or inappropriate usage of antimicrobials can delay the 
diagnosis of non-infectious causes of clinical signs, delay the resolution of an 
infection, and  select for growth of resistant bacterial populations, including the 
causative pathogen resistant to the antimicrobial used. Other negative aspects 
include unnecessary adverse effects of the drug treatment, and increased costs, 
including repeated veterinary visits or prolonged hospitalization (Gould, 2009, 
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Guardabassi and Prescott, 2015).When bacterial culture and antimicrobial 
susceptibility are used, the guiding of treatment towards rational and prudent 
antimicrobial use in individual patients lowers the amount of unnecessary or 
inappropriate use of antimicrobials in respective animal species (Bartges, 2004, 
Guardabassi and Prescott, 2015, WHO, 2014b). As the need for antimicrobial 
treatment may be urgent, empirical treatment is sometimes indicated while 
waiting for culture and susceptibility results. Prudent use of antimicrobials 
therefore includes considering likely pathogens and their susceptibility patterns 
when choosing empirical treatment   
The accumulated results of previous susceptibility testing from specific 
populations are invaluable when selecting such empirical therapy and to 
monitor trends in antimicrobial resistance. However, published surveillance 
reports on antimicrobial resistance in dogs are currently relatively few, and 
much baseline data on antimicrobial susceptibility needed to inform clinical 
therapy decisions as well as guide in policy recommendations is lacking. An 
increased surveillance of antimicrobial resistance would also permit the early 
detection of resistant strains and support investigation of outbreaks.  The need 
for increased surveillance of antimicrobial resistance in companion animals, 
has been recognized. Importantly, such surveillance should include not only 
cultures from patients that are “worst case scenarios”, but a broad, 
representative population so that the actual levels of antimicrobial resistance 
are reflected (Guardabassi and Prescott, 2015, Weese, 2008a, Prescott et al., 
2002, WHO, 2014a, Weese, 2008c). 
 
1.1.3 Interpretation and use of antimicrobial susceptibility results 
 
A number of in-vitro antimicrobial susceptibility testing methods are available, 
and suitable for veterinary use, for example E-test, agar dilution, broth 
microdilution and disc diffusion. Comparison of such methods are outside of 
the scope of this thesis. However, it is worth noting that use of internationally 
accepted procedures is important not only as an in-house best-practice, but also 
to facilitate comparison of data from different studies (Schwarz et al., 2010, 
Dehaumont, 2004) . 
Two different types of interpretive criteria are available: epidemiological 
cut-off values (www.eucast.org) and clinical breakpoints. Epidemiological cut-
off values separate isolates without phenotypically reduced susceptibility, i.e. 
wild-type isolates, from isolates with reduced susceptibility without reference 
to clinical efficacy are suitable for monitoring purposes. Clinical breakpoints 
on the other hand are intended to predict clinical efficiency of the tested 
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antimicrobial for treatment of the tested bacterial species in an individual 
patient. When recommendations for clinical breakpoints are developed for 
laboratory use, the results of clinical efficacy studies, dosing and route of 
administration of the antimicrobial agents, the drug’s pharmacokinetic and 
pharmacodynamic parameters in the respective animal species are taken into 
account (CLSI, 2008). The laboratory using these clinical breakpoints usually 
present the results to the clinician as a bacterial isolate being susceptible, 
resistant, or intermediate to the respective antimicrobial (Bywater et al., 2006, 
Schwarz et al., 2010). 
Internationally accepted breakpoints for specific disease conditions caused 
by a particular bacterial species in defined animal host species are not always 
available. Furthermore, some results will be borderline intermediate- 
susceptible, or intermediate- resistant, although only reported as either 
susceptible or resistant. (Schwarz et al., 2010, Bywater et al., 2006).  
The clinician has to use the susceptibility results from the laboratory 
responsibly. The clinical assessment is vital. For example, a satisfactory 
response to an antimicrobial treatment does not indicate a need for change of 
antimicrobial agent used despite the subsequent culture and susceptibility 
results yielding a pathogen intermediately resistant, to that agent. The 
relevance and likelihood of the bacterial species cultured actually being the 
cause of the clinical infection has to be taken into account. Resampling the 
infected site can be performed to address a seemingly discordant (incongruous) 
culture result vs. clinical suspicion, including cases where contamination of the 
sample is suspected.  
The term multiresistance has been used inconsistently in the literature. It 
has been suggested that the term multiresistance exclusively should refer to 
acquired resistance properties, i.e. constitutive (innate, primary) resistance 
should not be included (Schwarz et al., 2010, Hoekstra and Paulton, 2002, 
Guardabassi and Prescott, 2015). Furthermore, to label an isolate as multidrug 
resistant, acquired resistance to three or more classes of antimicrobial agents 
should be detected. The prevalence of MDR pathogens in a study might 
increase or decrease depending on what antimicrobials are included in the 
investigation. This could in turn influence the clinicians’ perception of the need 
for use of broad-spectrum antimicrobials. Investigations on the prevalence and 
importance of MDR pathogens should preferably exclude agents to which the 
bacteria are intrinsically resistant, as well as antimicrobials not relevant for 
treatment of the bacterial infection in question from a clinical viewpoint 
(Schwarz et al., 2010, Hoekstra and Paulton, 2002, Guardabassi and Prescott, 
2015). For example, resistance to aminopenicillins in E.coli isolates in UTI is 
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of interest, but penicillin is not indicated for treatment of skin and soft tissue 
infections caused by E.coli. 
1.2 Urinary tract infections  
Bacterial urinary tract infection (UTI) is a common clinical problem in dogs 
and among the most common reasons for antimicrobial therapy, with 
approximately 14% of all dogs having at least one episode of UTI during their 
lifetime (Ling, 1984, Thompson et al., 2011a). Female dogs are more 
commonly affected than males. The by far most common form is a simple 
uncomplicated lower UTI, which is a sporadic bacterial infection of the 
bladder. A UTI can also include the upper urinary tract (upper UTI), most 
commonly the renal pelvis, as well as multiple sites, including the ureter, 
bladder, urethra, prostate, or vagina (Ling, 1984, Cohn et al., 2003, Thompson 
et al., 2011a, Ball et al., 2008, Seguin et al., 2003, Ling et al., 2001). 
1.2.1 Complicated and recurrent urinary tract infections 
The term complicated UTI has been used to describe both upper and lower UTI 
that occur in the presence of an anatomic or functional abnormality or a 
comorbidity that predisposes the patient to persistent infection, recurrent 
infection, or treatment failure. Conversely, the term uncomplicated UTI is used 
to describe UTI in patients where no underlying structural, neurologic, or 
functional abnormalities exist (Weese et al., 2011b, Ling et al., 1980, Jessen et 
al., 2015).  
Most UTI in dogs are uncomplicated and occur as single episodes, and in 
cases of persistent and recurrent UTI predisposing factors can usually be 
identified. Examples of such predisposing factors include abnormal 
micturition, anatomic defects of the urinary tract, abnormal urothelium, altered 
urine composition or impaired immunity (Thompson et al., 2011a, Ling, 1984, 
Weese et al., 2011a). Recurrent UTI can also occur in dogs where no 
predisposing factors have been diagnosed (Ling, 1984, Weese et al., 2011b, 
Thompson et al., 2011a). In one study 4.5% of dogs with uncomplicated UTI 
had recurrent UTI (Seguin et al., 2003). Another retrospective study found 
only 0.3% of diagnosed UTI in dogs to be either recurrent or persistent (Norris 
et al., 2000).  
Clinically applicable definitions of reinfection, relapse and refractory 
infections are presented in for example the Antimicrobial Use Guidelines for 
Treatment of Urinary Tract Disease from the International Society for 
Companion Animal Infectious Diseases (Weese et al., 2011b). Reinfection is 
defined as recurrence of a UTI within 6 months of cessation of previous, 
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apparently successful treatment and isolation of a different microorganism. 
Relapse is defined as recurrence of a UTI within 6 months of cessation of 
previous, apparently successful treatment and isolation of an indistinguishable 
organism from the one that was present previously, which is presumably 
because of failure to completely eliminate the pathogen. Furthermore, relapses 
can generally be expected to occur earlier than reinfections (i.e., within weeks 
rather than months) and they are characterized by a period of apparent bladder 
sterility during treatment. Finally, refractory infection is defined as persistently 
positive culture results during treatment despite in vitro susceptibility to the 
antimicrobial, with no period of elimination of bacteriuria during or after 
treatment (Weese et al., 2011b). 
Differentiation of persistent infections, relapses or re-infection in clinical 
cases of canine UTI is often difficult. Ideally, genotyping should be included to 
investigate whether the same strain is present, in addition to identification of 
the bacterial species and investigation of the antibiograms. In clinical practice 
such analyses are, with rare exceptions, not available. Furthermore, changes in 
susceptibility can occur in individual strains, and different strains can be 
genotypically indistinguishable (Ball et al., 2008, Weese et al., 2011b).  
Culture and susceptibility testing should be repeated in persistent- or re-
infections, regardless of whether this has already been performed on previous 
bouts of UTI. Bacterial resistance to the antimicrobial administered is a 
possible contributing factor, or the major cause of lack of clinical improvement 
in persistent, relapsing or reoccurring UTI. The possibility of poor owner- or 
patient compliance should as always be included in the investigation of 
bacterial infections not responding as expected to the prescribed treatment. 
Notably, it has been shown in humans that the proportion of resistant E coli 
isolated from complicated urinary tract infections is significantly higher than 
the proportion isolated from uncomplicated cases. Furthermore, previous 
antimicrobial treatment of UTI could potentially have an impact on the 
resistance profiles of the dog´s resident bacterial flora, facilitating growth of 
resistant bacteria. The possibility of underlying abnormalities as well as of the 
bacteria being capable of evading host immune defence mechanisms should 
not be overlooked. The predisposing causes that complicate the UTI need to be 
diagnosed, managed and if possible eliminated (Thompson et al., 2011a, 
Weese et al., 2011a). The distinction between complicated UTI and 
inefficiently treated UTI determines the prognosis as well as recommendations 
for further and future investigations and treatments (Thompson et al., 2011a, 
Weese et al., 2011b). 
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1.2.2 Bacterial pathogens 
Most UTI are thought to result from ascending infections, with the causative 
bacterial pathogens most often originating either from the gastrointestinal tract 
or from the skin surrounding the vulva and prepuce. The bacteria ascend via 
the urethra to the urinary bladder where they adhere and colonize the urothelial 
surface. Ascension of bacteria from the lower urinary tract is the primary route 
for upper UTI. Upper UTI can also, though rarely, be of 
haematogenous/lymphatic origin, or due to direct extension from surrounding 
tissues (Thompson et al., 2011a, Seguin et al., 2003, Bartges, 2004, Ling et al., 
1980). It is therefore not unexpected that E. coli, Staphylococcus 
pseudintermedius (S. pseudintermedius), S. aureus, beta haemolytic 
Streptococcus spp., Proteus spp., Enterococcus spp., and Klebsiella spp. 
account for 95% or more of all urinary isolates in dogs (Seguin et al., 2003, 
Bartges, 2004, Ling et al., 2001, Weese et al., 2011a, Ogeer-Gyles et al., 
2006a). The by far most commonly cultured bacterial species isolated from 
canine urine -as well as from human and feline UTI- is E. coli which in various 
studies has accounted for more than half of all positive urine cultures (Seguin 
et al., 2003, Bartges, 2004, Ling et al., 2001, Ogeer-Gyles et al., 2006a, Weese 
et al., 2011b).  
 
1.2.3 Diagnosis  
Clinical signs of UTI include dysuria, pollakiuria, and/or increased urgency of 
urination. The clinical signs are not pathognomonic for infection. The 
likelihood of the presenting complaints being due to clinically significant UTI 
has to be evaluated by the clinician. Urinalysis is useful in differentiating an 
uncomplicated lower UTI from other disorders causing the clinical signs, as 
well as in further investigations of possible underlying causes of UTI, such as 
endocrine disorders. A dipstick analysis is of value, as it often detects 
hematuria and proteinuria in cases of UTI. Notably, the dipstick analyses for 
nitrite (bacteria) and leukocyte esterase are designed for use in people and are 
not reliable tests for canine and feline patients. A urine sediment examination 
should therefore in addition be performed to identify pyuria and bacteriuria. 
Presence of hematuria, proteinuria and evidence of inflammation together with 
appropriate findings at clinical examination and clinical signs increase the 
suspicion of a bacterial infection of the urinary tract. As none of the findings 
are pathognomonic, including a urine culture as a part in the investigation still 
remains the definitive diagnostic test of UTI (Bartges, 2004, Weese et al., 
2011b, Smee et al., 2013, Ball et al., 2008, Seguin et al., 2003). Bacterial 
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culture and susceptibility testing can not only confirm the presence of 
infection, but also aid in selection of relevant antimicrobial therapy. 
Notably, detection of bacteria in urine samples occurs not only in clinical 
cases of UTI, but also in asymptomatic, or subclinical bacteriuria which can be 
defined as the presence of bacteria in the urine as determined by positive 
bacterial culture in the absence of clinical and cytological evidence of UTI. 
Numerous reports record the prevalence of bacteriuria in dogs with known 
underlying clinical disease (e.g. diabetes mellitus, hyperadrenocorticism, and 
urolithiasis) or in dogs after medical intervention (e.g. urinary catheterisation, 
immunosuppression). (Thompson et al., 2011b, Torres et al., 2005, Bubenik et 
al., 2007, McGhie et al., 2014, Weese et al., 2011b, Smee et al., 2013). 
Whether antimicrobial treatment should be administered to dogs with 
subclinical bacteriuria remains a controversial topic. In some cases, the 
bacteria present in animals with an asymptomatic bacteriuria may actually 
provide protection against colonization of the urinary tract with more 
pathogenic strains of bacteria (Thompson et al., 2011a, Barsanti, 2006). The 
Antimicrobial Use Guidelines for Treatment of Urinary Tract Disease from the 
International Society for Companion Animal Infectious Diseases states that 
treatment may be considered if there is concern that there is a particularly high 
risk of ascending or systemic infection (e.g., immunocompromised patients, 
patients with underlying renal disease) or that the bladder may be a focus of 
extra urinary infection. Importantly, treatment should not be used as a 
replacement for proper diagnosis and management of the underlying cause 
(Weese et al., 2011a).  
The relevance of the identified species in UTI in dogs has to be included in 
interpretation of the significance of the detection of bacteria in a urine sample. 
In addition, colony counts (the level of bacterial growth), can be used as an aid. 
Quantitative aerobic bacterial culture of urine provides an estimate of the 
number of bacteria present. It has been suggested that as urine normally is 
sterile, any level of bacterial growth from samples collected by cystocentesis 
may be significant, provided that the sample collection was performed 
properly. It has also been proposed that urine from a UTI in dogs typically 
contain ≥103 colony forming units (CFU)/mL. For samples collected via 
catheter, bacterial counts ≥104 CFU/mL in male and ≥105 in female dogs could 
be considered significant and for free-catch samples ≥ 105 CFU/mL (Bartges, 
2004, Comer and Ling, 1981, Weese et al., 2011b). 
Although infection with more than one species can occur, detection of 
several potential pathogens should be interpreted with caution, as the majority 
(72-91 %) of UTI in dogs are caused by a single bacterial species (Ball et al., 
2008, Rowlands et al., 2011, Weese et al., 2011b, Ling et al., 2001). 
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1.2.4 Collection and submission of urinary samples for bacterial analyses 
Bacteria detected in a urine sample can also be present as a result of 
contamination of the sample. Poor sampling technique can lead to 
contamination with resident bacterial flora in the urethra, prepuce and vagina, a 
flora which includes potential pathogens of the sample. In veterinary patients, 
collection of urine for culture by cystocentesis is considered the gold standard 
as it avoids bacterial contamination with faecal bacteria and bacteria from the 
distal urogenital tract. However, it is not uncommon for both cystocentesis and 
second-best options in trying to avoid bacterial contamination of the sample, 
like catheterization or securing a midstream sample, to be unrealistic 
alternatives when collecting the sample due to either cost or practical problems 
(Ling et al., 1980, Rowlands et al., 2011, Comer and Ling, 1981, Thompson et 
al., 2011a). 
Handling and processing of the collected sample can affect the culture 
results. Time from sample occasion to processing may in itself affect the 
culture results, including assessment of yielded growth on the agar plates. 
Immediate culture (within four hours) after sampling is ideal to avoid false-
positive and false- negative culture results. Both rapid multiplication of 
bacteria (doubling in number in about 45 minutes) and a decrease in number 
has been reported from studies investigating urine samples kept at room 
temperature (Ling et al., 1980, Lulich and Osborne, 2004, Tivapasi et al., 
2009). In-house culture should however not be attempted if the knowledge and 
practical settings for culture and identification of bacterial species and their 
antimicrobial susceptibility patterns are lacking. In a practice setting, bacterial 
samples are therefore often referred to an external laboratory for culture and 
susceptibility. The optimal submission method minimises misleading results, 
by restricting growth of contaminants while preserving pathogens (Ling et al., 
1980, Tivapasi et al., 2009, Smee et al., 2013, Weese and Jalali, 2014).  
Recommendations for storing urine samples that are not immediately 
cultured include refrigeration within 1 or 2 hours of collection. Refrigeration 
(4°C) of the samples might be beneficial not only during temporary storage but 
also during shipping. One study recorded that quantitative bacterial counts 
differed after 6 hours of refrigerated storage, but without a change in 
interpretation of the clinical significance, and concluded that it is acceptable 
for urine to be refrigerated in a closed container for up to six hours prior to 
culture (Padilla et al., 1981). On the other hand, false negative results (failure 
of bacteria to grow) might also occur when specimens are refrigerated for long 
periods of time. In clinical practice, samples are usually not refrigerated during 
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transportation (Penna et al., 2010, Rowlands et al., 2011, Weese et al., 2011b, 
Tivapasi et al., 2009). 
Submission of the sample as preincubated media; agar plates or urine 
dipstick paddles for veterinary use with an appropriate medium is another 
possible way of supporting maintenance of relevant microorganisms without 
overgrowth. Dipstick paddles consist of a culture paddle embedded with 2 
standard culture media. Preincubation at the clinic gives the clinician the 
possibility to screen samples for bacterial growth, as part of the investigation of 
UTI, and subsequently submit only positive culture for further analyses. After 
24 hours incubation the dipstick paddles/agar plates with positive growth can 
be sent to an appropriate microbiology laboratory (Ybarra et al., 2014, Weese 
et al., 2011b, Smee et al., 2013, Ling et al., 1980, Ling et al., 2001). 
In human medicine, a relatively high overall sensitivity and specificity for 
detection of relevant bacteriuria has been reported for urinary dipslides (e.g. 
approximately 70% and 82-94% respectively) when compared to cultures 
performed in a diagnostic microbiology laboratory (Anacleto et al., 2009, 
Winkens et al., 2003, Scarparo et al., 2002). A recent study of a commercially 
available veterinary dipslide system showed similar results (Ybarra et al., 
2014).  
Relevant publications on the use of bacterial swabs specifically for canine 
urinary samples are lacking. A few studies have investigated the use of boric 
acid-glycerol-sodium formate tubes for submission of urine samples for 
culture, and compared the culture results to immediate culture of fresh urine, as 
well as either culture from urine kept in a sterile plastic tube or in a dipslide 
tube, with conflicting results (Rowlands et al., 2011, Perrin and Nicolet, 1992). 
Rowlands and co-workers concluded that urine samples should be submitted 
to the laboratory in a plain sterile tube (Rowlands et al., 2011). In the study by 
Perrin and co-workers, preserving samples in boric acid was beneficial. 
Samples sent in the boric acid and in the dip-slide tube showed comparable 
culture results, while culture of the samples sent in a sterile plastic tube yielded 
53% false positive results in comparison with those of the samples preserved in 
boric acid (Perrin and Nicolet, 1992). 
Ling and co-workers reported that Proteus spp. were isolated more 
frequently from urine specimens collected by catheterisation or midstream 
catch than by cystocentesis, and in a study by Bubenik and co-workers, 
Enterobacter spp. and Staphylococcus spp. were more frequently isolated from 
catheterised dogs (Bubenik et al., 2007, Ling et al., 2001). To what extent the 
prevalence of various bacterial agents is influenced by sample technique and 
sample material is otherwise not well described, and further studies specifically 
designed to compare sample methods and sample materials are warranted.  
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Other factors that have been reported to possibly influence the distribution 
of bacterial pathogens in urine cultures include the dogs’ gender, urine 
concentration and of acidity of the urine, but the results published are 
conflicting (Norris et al., 2000, Cohn et al., 2003, Tivapasi et al., 2009, Ling et 
al., 2001). 
 
1.3 Surgical site infections  
Infection is an inherent risk of surgery, and surgical site infections (SSI) cannot 
be expected to be completely eliminated. Some SSI are preventable, others are 
not, for example due to the surgical area being infected or contaminated prior 
to an emergency surgery (Nelson, 2011, Mangram et al., 1999, Eugster et al., 
2004).  
Surgical site infections are among the most common nosocomial infections 
in human patient populations (Barnett, 2007, Mangram et al., 1999). They 
account for 16% of nosocomial infections in all patients and 38% of 
nosocomial infections among surgical patients in the United States (Mangram 
et al., 1999). SSI has been described as a complication of 3.6% to 18.1% of 
small animal surgical procedures with significant variation associated with 
surgery type; infection rates for clean surgical procedures tend as expected to 
be in the lower range: from 3.6% to 5.8% (Eugster et al., 2004, Vasseur et al., 
1988, Vasseur et al., 1985, Weese and Halling, 2006, Frey et al., 2010, Brown 
et al., 1997, Whittem et al., 1999, Weese, 2008c). SSI can affect the success of 
initial surgical intervention and delay healing. Furthermore they can incur 
additional costs (Turk et al., 2015, Nelson, 2011, Nicoll et al., 2014). Although 
development of SSI is multifactorial, and published scientific data on 
prevention of SSI in small animal medicine relatively limited, much 
information on key factors in preventing SSI can be extrapolated from human 
medicine (Nelson, 2011, Weese, 2008c, Mangram et al., 1999). 
As for other HAI, development and implementation of proper infection 
control programs to prevent spread of antimicrobial resistant bacteria in clinics 
and hospitals, as well as surveillance protocols including patterns of 
antimicrobial resistance have in human medicine been shown to be key 
components in reducing SSI rates. Well-known key preventive measures 
specifically aimed at reducing the risk of SSI include adherence to aseptic 
principles and good surgical techniques as well as proper preparing and caring 
of the dog and the surgical area prior to, during, and after surgery (Nelson, 
2011, Dohmen, 2008, Mangram et al., 1999, Beal et al., 2000, Brown et al., 
1997, Barnett, 2007, Eugster et al., 2004).  
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Surgical site infections are, as other bacterial HAI, increasingly complicated 
by the emergence of MDR bacteria. The risk of SSI developing due to 
contamination with resident environmental MDR bacteria in health care 
facilities is well known in human medicine. In small animal medicine the risk 
of MDR bacteria causing SSI in dogs has been increasingly recognized. 
Although the morbidity and mortality associated with MDR SSI have not been 
thoroughly investigated in small animal practice, it is reasonable to assume that 
they, as shown in human medicine, are associated with poorer outcomes 
including increased mortality (Wieler et al., 2011b, Weese, 2008c, Dohmen, 
2008, Barnett, 2007, Owens and Stoessel, 2008, Bergstrom et al., 2012, Weese 
et al., 2012, Nicholson et al., 2002, Bratzler et al., 2013).  
 
1.3.1 Bacterial pathogens 
In humans, the patients’ endogenous flora is the major source of bacteria 
infecting surgical wounds (Mangram et al., 1999). The endogenous skin flora 
is also recognized as an important cause of SSI in dogs, as aseptic preparation 
of the skin cannot completely eliminate skin-associated bacteria, especially not 
bacteria residing in the deeper parts of the skin such as the hair follicles and 
sebaceous glands. Both superficial and deeper infection can be the result, as the 
bacteria can enter deeper tissues during the initial incision. Bacterial species 
known to be part of the canine skins endogenous flora, as well as pathogens 
important in canine dermatitis are therefore expected to be prevalent findings 
in canine SSI (Nelson, 2011, Johnson, 2002, Mangram et al., 1999). These 
include staphylococci, of which S. pseudintermedius is the by far most frequent 
bacterial pathogen in canine dermatitis- one of the most common reason for 
antimicrobial treatment in dogs, and for dog owners seeking veterinary care for 
their animal. Besides S. pseudintermedius, the most clinically relevant 
staphylococci in canine medicine are S. aureus, and the species more recently 
recognized as a pathogenic species implicated in canine infections 
Staphylococcus schleiferi subsp. coagulans (S. schleiferi) (Bannoehr and 
Guardabassi, 2012, Devriese et al., 2005, Frank et al., 2003, May et al., 2005, 
Morris et al., 2006, Cox et al., 1984) 
Commensal flora expected to be present if the surgical area or procedure 
involves gut, genital and urinary tract, or respiratory tract include E.coli, 
Proteus spp., Enterobacter spp., Klebsiella spp., Pseudomonas spp. and beta 
haemolytic Streptococcus spp. (Nelson, 2011, Weese, 2013, Priestnall and 
Erles, 2011, Quinn P.J., 2011). Although these bacterial species are less 
commonly associated with pyoderma than staphylococi, they are cultured from 
healthy and diseased canine skin and are recognized as pathogens in skin 
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disease. Endogenous flora can also be transferred to intact skin at the planned 
incision site before the procedure, for example through the dogs grooming 
behaviour (Nelson, 2011, Weese, 2013, May, 2006, Priestnall and Erles, 2011, 
Turk et al., 2015, Nicoll et al., 2014, Summers et al., 2012, Rodrigues 
Hoffmann et al., 2014, Hillier et al., 2014, Quinn P.J., 2011, Eugster et al., 
2004). 
Exogenous sources of surgical contamination include the surgical 
equipment, the physical environment and bacteria on hands and clothes of 
personnel.  In addition, bacterial contamination of affected tissues can also 
stem from for example a traumatic injury, including bite wounds (Nelson, 
2011, Johnson, 2002). 
The frequency of exogenous versus endogenous flora causing SSI in dogs is 
not well described. Many of the risk factors that might contribute to exogenous 
infection such as poor surgical technique (skill of the individual surgeon), lack 
of aseptic preparation of the surgical team, inappropriate ventilation in the 
operation theatre and other environmental factors described in human medicine 
are probably applicable to veterinary medicine.  Some risk factors, such as 
numbers of people in the operating room, student surgeon, prolonged 
anaesthetic and surgical time, duration of hospitalization and drain placement 
have also been described as associated with SSI in dogs, but knowledge of the 
relative importance of each of these factors is relatively limited (Boerlin et al., 
2001, Nelson, 2011, Weese, 2008c, Vasseur et al., 1985, Vasseur et al., 1988, 
Beal et al., 2000, Brown et al., 1997, Nicholson et al., 2002, Heldmann et al., 
1999, Mangram et al., 1999). 
 
1.3.2 Diagnosis  
The diagnosis of SSI requires interpretation of both clinical and laboratory 
information and is subject to a certain degree of subjectivity. The clinical 
distinction between infection and inflammation can be difficult, as some local 
inflammation or serous discharge can be expected at the incision site of a 
surgical procedure. The clinical signs due to inflammation may be 
indistinguishable to those of an added infection. Various definitions have also 
been used for postoperative SSI in veterinary medicine publications (Eugster et 
al., 2004, Nelson, 2011, Vasseur et al., 1988, Whittem et al., 1999, Billings et 
al., 1990, Brown et al., 1997). Bacterial culture is important to verify an 
ongoing infection, as well as, together with antimicrobial susceptibility testing, 
guide in selecting an appropriate antimicrobial therapy, if such therapy is 
necessary.  
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Surgical wound criteria intended to aid in comparisons between studies and 
for surveillance of SSI have been developed by among others The Centers for 
Disease Control and Prevention National Nosocomial Infections Surveillance 
(NNIS) (Mangram et al., 1999) and The US Centers for Disease Control and 
Prevention (CDC) (Horan et al., 1992). A clear correlation between SSI rates 
and four described categories of wound contamination; clean, clean-
contaminated, contaminated, and dirty has been reported in human medicine 
(Mangram et al., 1999, Horan et al., 1992). The CDC and NNIS classify SSI as 
superficial incisional, deep incisional or organ/space (Horan et al., 1992, 
Mangram et al., 1999). When evaluating SSI in dogs an objective definition is 
desirable for facilitating comparison of veterinary studies. However, such 
classifications have rarely been used in publications on canine SSI (Weese, 
2008c, Eugster et al., 2004, Nelson, 2011).   
Empirical antimicrobial treatment might be indicated while awaiting 
culture- and susceptibility results (Nelson, 2011, Nicholson et al., 2002).  
Furthermore, perioperative antimicrobial treatment is widely used to prevent 
SSI. The goal of perioperative antimicrobial therapy is to reduce the risk of 
infection while having minimal negative impact on the patient’s microflora and 
minimizing the risk of antimicrobial-associated complications. Standard 
guidelines in human medicine state that antimicrobials should be administered 
intravenously so that there are adequate serum and tissue concentrations at the 
time of surgery and at a most a few hours after the procedure (Mangram et al., 
1999, Bratzler et al., 2013, Bratzler et al., 2005). Less information is available 
in veterinary medicine. Concerns with postoperative antimicrobial 
administration are possible limited benefits in the prevention of SSI paired with 
an increased risk of the development of MDR infections. As conflicting results 
regarding the benefit of perioperative treatment in various types of surgical 
procedures are present, the use of antimicrobials remains controversial e.g. in 
clean procedures (Nelson, 2011, Weese, 2008c, Eugster et al., 2004, Bratzler et 
al., 2013, Weese and Halling, 2006, Brown et al., 1997, Vasseur et al., 1985, 
Vasseur et al., 1988). 
As mentioned above, empirical treatment is becoming more difficult as 
antimicrobial resistance increases, and the increased awareness of the risk of 
nosocomial infections with MDR bacteria might pressure attending 
veterinarians to use antimicrobials other than traditional first-line 
antimicrobials (Guardabassi et al., 2004b, Weese, 2008a, Guardabassi and 
Prescott, 2015, Wieler et al., 2011b). However, the focus in veterinary studies 
on SSI in dogs have tended to be directed towards investigating possible risk 
factors for developing an infection, and few recent veterinary studies have 
investigated the relative growth of pathogenic bacteria, including susceptibility 
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patterns of the isolated pathogens in canine SSI where less complicated 
procedures are included (Eugster et al., 2004, Nicholson et al., 2002, Beal et 
al., 2000, Billings et al., 1990, Brown et al., 1997, Frey et al., 2010, Heldmann 
et al., 1999, Mayhew et al., 2012, Vasseur et al., 1985, Vasseur et al., 1988, 
Weese and Halling, 2006, Whittem et al., 1999, Turk et al., 2015, Nicoll et al., 
2014). 
 
1.4 Methicillin-resistant Staphylococcus pseudintermedius 
Staphylococcus intermedius was first described in 1976 (Hajek, 1976).  More 
recent work showed that isolates phenotypically identified as S. intermedius 
were three distinct species, S. intermedius, S. pseudintermedius and 
Staphylococcus delphini. These three species are together referred to as the 
Staphylococcus intermedius group (SIG) (Bannoehr et al., 2007, Devriese et 
al., 2005, Sasaki et al., 2007b). Staphylococcus pseudintermedius is a skin and 
mucous membrane commensal as well as the most important staphylococcal 
pathogen in dogs. It has also been labelled the overall most frequently bacterial 
pathogen isolated from clinical canine specimens. As mentioned above it is the 
by far most frequent bacterial pathogen in skin- and ear infections (Bannoehr 
and Guardabassi, 2012, Devriese et al., 2005, May et al., 2005), and canine 
dermatitis is one of the most common reasons for antimicrobial treatment in 
dogs, as well as for dog owners seeking veterinary care for their animal. 
Staphylococcus pseudintermedius is also recognized as an important pathogen 
in various soft tissue infections (Bannoehr and Guardabassi, 2012, Frank et al., 
2003, May et al., 2005, Morris et al., 2006, Cox et al., 1984).  
Staphylococcus pseudintermedius is traditionally identified by colony 
morphology and standard phenotypic tests. Owing to a lack of unique 
biochemical markers, differentiation between the members of the SIG is 
difficult unless genotypic methods are used (van Duijkeren et al., 2011a, 
Bannoehr and Guardabassi, 2012). Several methods are available, and used in 
various publications including a multiplex PCR method for species 
identification of coagulase-positive staphylococci targeting the nuc gene locus, 
matrix assisted laser desorption ionization–time-of-flight mass spectrometry 
(MALDI-TOF MS) and polymerase chain reaction–restriction fragment length 
polymorphism (PCR-RFLP) (Bannoehr and Guardabassi, 2012, van Duijkeren 
et al., 2011a). However, as the vast majority of canine strains are S. 
pseudintermedius, the risk of species misidentification in routine diagnostics is 
low for canine specimens. Furthermore, the impact that such sporadic 
misidentification may have on clinical practice and patient care are probably 
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negligible. After the reclassification of S. intermedius to S. pseudintermedius, it 
has therefore been proposed that all canine isolates should be termed S. 
pseudintermedius, unless proven otherwise by genetic typing methods 
(Devriese et al., 2009, Bannoehr and Guardabassi, 2012).  
Methicillin-resistant S. pseudintermedius (MRSP) was first reported in 
1999, from North America, and the first report on methicillin-resistant S. 
pseudintermedius (MRSP) in Europe was published in 2007 (Loeffler et al., 
2007, Gortel et al., 1999). Methicillin resistance in S. pseudintermedius, as 
well as in S. aureus is mediated by the mecA gene, which encodes a penicillin-
binding protein (PBP2a) that has a low affinity for all ß-lactam antimicrobials 
(Chambers, 1997, Kwon et al., 2006). This means that MRSP and MRSA 
strains are resistant to all beta-lactam antimicrobials, i.e. penam penicillins, 
including clavulanic acid potentiated preparations, cephalosporins and 
carbapenems which are considered to be last resort antimicrobials in human 
medicine (Frank and Loeffler, 2012, WHO, 2012). The mecA gene has also 
been identified in other staphylococci, including S. schleiferi (Loeffler et al., 
2007, Cain et al., 2011). 
Most publications on MRSP have focused on isolates from dogs, and only 
few isolates from other animals have been investigated. MRSP has however 
been isolated from cats, and some other animal species including horses. Cats 
are less frequently colonized by S. pseudintermedius, less often suffering from 
staphylococcal infections, and are therefore expected to also be less frequently 
colonized and infected with MRSP (Wettstein et al., 2008, Morris et al., 2006, 
Ruscher et al., 2009, Kadlec and Schwarz, 2012, Nienhoff et al., 2011). 
Resistance to oxacillin or cefoxitime is used as an indicator of methicillin 
resistance, but the final identification of MRSP and MRSA isolates is based on 
the presence of the mecA gene. Detection of mecA via polymerase chain 
reaction (PCR) has been recommended for diagnosing methicillin resistance 
(van Duijkeren et al., 2011a, Kadlec and Schwarz, 2012).  
Isolation of MRSP from dogs has been reported with increasing frequency 
worldwide (Weese and van Duijkeren, 2010, Lehner et al., 2014, van 
Duijkeren et al., 2011a, Ruscher et al., 2010, Moodley et al., 2014). Reported 
prevalence rates of MRSP positive dogs in the community, or specifically in 
dogs with skin disease vary widely, e.g. 0-7% in dogs (Griffeth et al., 2008, 
Vengust et al., 2006, Kania et al., 2004, Hanselman et al., 2008, Hanselman et 
al., 2009). In one study from a veterinary clinic in Japan, 30% of sampled dogs 
were MRSP positive (Sasaki et al., 2007a) (Sasaki et al., 2007a), and in two 
studies on dogs with pyoderma in China and Japan MRSP prevalence was 48% 
and 66% respectively (Feng et al., 2012, Kawakami et al., 2010).  
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In Sweden, data on resistance in S. pseudintermedius in isolates from 
Swedish dogs referred to the National Veterinary Institute from veterinary 
clinics and hospitals has been reported since 1992, and since 2008, methicillin 
resistant coagulase positive staphylococci are notifiable in Sweden. The first 
MRSP isolates in Sweden were described in the year 2006, when 13 dogs were 
confirmed to be infected with MRSP.  The number of confirmed canine MRSP 
infections quickly increased. In 2009, more than 120 MRSP isolates were 
confirmed and hence reported (SVARM, 2009). However, after the peak in 
number of isolates in 2009, the number of isolates detected per year decreased, 
and during the year 2013 in total 33 isolates were reported (SWEDRES-
SVARM, 2013, SVARM, 2011). 
DNA-based investigations of MRSP isolates including use of multi-locus 
sequencing (MLST), have shown that MRSP isolates belonged to five distinct 
cloneal lineages, labelled sequenced types (ST) numbers ST29, ST68, ST69, 
ST70 and ST71, and that MRSP clones were not shared between Europe and 
North America. Furthermore, within the five ST- types two predominant 
lineages have been identified; ST68 in the USA and ST71 in Northern Europe 
(Bannoehr et al., 2007, Perreten et al., 2010, Ruscher et al., 2010). In contrast, 
methicillin-susceptible S. pseudintermedius (MSSP) is, based on current 
knowledge, not regarded as being clonally distributed, and it has been 
postulated that the mecA gene has been acquired by different S. 
pseudintermedius strains (Bannoehr et al., 2007, Bannoehr and Guardabassi, 
2012, Black et al., 2009). It is also thought that the mecA gene is likely to have 
originated from coagulase negative staphylococci (members of the 
Staphylococcus sciuri group) that colonize both animals and humans 
(Tsubakishita et al., 2010, Frank and Loeffler, 2012).  
It is considered unlikely that the rapid emergence and spread of MRSP is 
due to frequent transmissions of SCCmec, the genetic element that contains 
mecA. Differences in the genetic makeup of antimicrobial resistance in MRSP 
and MSSP, including difference in resistance genes conferring resistance to 
tetracyclines and macrolides, together with the dominance of a few MRSP 
clones points towards a successful spread of MRSP clones, as opposed to 
frequent acquisition of methicillin resistance in MSSP. MRSP and MRSA are 
thought to have evolved separately through adaptation to their respective hosts. 
MRSP emerged several decades after emergence of MRSA in human medicine 
and some of the SCCmec types found in MRSP have never been described in S. 
aureus (Bannoehr and Guardabassi, 2012, Guardabassi et al., 2004b, Perreten 
et al., 2010, Bannoehr et al., 2007).   
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1.4.1 Clinical implications of canine MRSP infection 
Investigations of clinical presentations of MRSP infection are scarce, but there 
is currently no evidence that MRSP is more invasive or able to cause different 
types of disease than MSSP. Published clinical reports on MRSP infections 
have mirrored infections known to be caused by MSSP. The majority of 
reported MRSP infections have been superficial and deep pyoderma, ear and 
wound infections, and postoperative infections. Other reported infections 
include urinary tract infections and respiratory infections (Beck et al., 2012, 
van Duijkeren et al., 2011a, Jones et al., 2007, Frank and Loeffler, 2012, 
Weese and van Duijkeren, 2010).  
Case analyses have to date not indicated any differences in severity and 
outcome between MRSP and MSSP infections, but studies of virulence factors 
in MRSP and MSSP are scarce (Loeffler et al., 2007, Morris et al., 2006, 
Weese et al., 2012, Fitzgerald, 2009, Bryan et al., 2012, Bannoehr and 
Guardabassi, 2012). 
Despite the lack of indications of differences in severity and outcome 
between canine MRSP and MSSP infections, MRSP infections present 
significant clinical challenges to veterinary surgeons. In addition to the broad 
range of important antimicrobials that are beta-lactam antimicrobials, MRSP 
strains often, in addition to mecA, carry a wide range of other antimicrobial 
resistance genes that confer resistance to almost all classes of antimicrobial 
agents routinely used in small animal practice. Often no clinically relevant pet 
authorized systemic antimicrobial drugs are effective (Kadlec et al., 2010, 
Perreten et al., 2010, Weese and van Duijkeren, 2010, van Duijkeren et al., 
2011a). 
The limited choice of effective veterinary antimicrobial agents available for 
treatment of MRSP is well recognized in Sweden, where more than 90% of 
MRSP isolates investigated between the year 2009 and 2011 were susceptible 
only to two of the antimicrobials licensed for use in dogs; fusidic acid and 
tetracycline. Some isolates have been resistant to tetracycline as well 
(SVARM, 2011).   
The few antimicrobials left for treatment of MRSP infections include 
antimicrobials such as linezolid, quinupristin/dalfopristin, rifampicin, 
vancomycin and local treatment with mupirocin; antimicrobials  that are used 
for decolonization or as last resort antimicrobials against methicillin-resistant 
staphylococci in humans. Use of such antimicrobials in dogs is therefore 
controversial (WHO, 2012, Weese, 2008b, Guardabassi et al., 2004b, Weese et 
al., 2015, Frank and Loeffler, 2012). The national guidelines on clinical use of 
antibiotics in dogs and cats from the Swedish Veterinary Association 
(www.svf.se) stated in the year 2009 that such antimicrobials should only be 
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used if necessary for animal welfare and where no other treatments are 
available. Furthermore, a specialist competence is to be involved, and the 
motivation for such treatment should be noted in the medical chart. The use of 
antimicrobials has subsequently been further restricted through legislation (The 
Swedish Board of Agriculture, www.jordbruksverket.se)  
Other antimicrobials include chloramphenicol, which is rarely used due to 
possible side effects, and to which European MRSP isolates often are resistant. 
European MRSP isolates are rarely susceptible to clindamycin, or 
fluoroquinolones (Kadlec and Schwarz, 2012, Perreten et al., 2010, Weese and 
van Duijkeren, 2010, van Duijkeren et al., 2011a, Kadlec et al., 2010, 
Guardabassi et al., 2004b, Guardabassi and Prescott, 2015). Furthermore, use 
of fluoroquinolones has been associated with an increased risk for isolation of 
MRSA. The use in treatment of MRSP is therefore controversial (Frank and 
Loeffler, 2012, Guardabassi and Prescott, 2015). 
Topical therapy include  using shampoos containing chlorhexidine, benzoyl 
peroxide or ethyl lactate, and treatment of focal lesions with chlorhexidine 
spray, benzoyl peroxide gel, fusidic acid or nisin. As with any antimicrobial, 
prudent use of topical products is indicated to prevent widespread resistance 
(Frank and Loeffler, 2012, van Duijkeren et al., 2011a).  
 
1.4.2 Zoonotic aspects 
Colonization with MSSP is uncommon in humans, even among people with 
frequent contact with animals. The low prevalence could be due to humans not 
being natural hosts for S. pseudintermedius as staphylococcal colonization in 
humans is dominated by S. aureus and Staphylococcus epidermidis (van 
Duijkeren et al., 2011a, Weese and van Duijkeren, 2010, Frank and Loeffler, 
2012, Hanselman et al., 2009). Rare cases of human infections with MSSP are 
reported, usually associated with dog-bite wounds (van Duijkeren et al., 2011a, 
Weese and van Duijkeren, 2010, Talan et al., 1989, Sasaki et al., 2007a). 
MRSP has been cultured from persons living in households together with a dog 
with an ongoing or previous MRSP infection, as well as in personnel working 
in veterinary clinics where MRSP infected pets were treated infrequently.  The 
prevalence of MRSP in humans living in households with dogs or working at 
small animal clinics has in various studies varied from less than one percent to 
14 % (Morris et al., 2010, Paul et al., 2011, Frank et al., 2009, Laarhoven et 
al., 2011, Ishihara et al., 2010). The presence of genetically similar, or 
indistinguishable isolates in pets and their owners has in some studies been 
confirmed (Guardabassi et al., 2004a, Soedarmanto et al., 2011, Zubeir et al., 
2007, van Duijkeren et al., 2008). As colonization of humans is thought to be 
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infrequent and transient, the risk of zoonotic transmission causing clinical 
infection with MRSP in humans is considered to be small. As for MSSP, 
reports on MRSP infections in humans are also rare. Still, persons colonized 
with MRSP may have a higher risk of developing MRSP infections in case of 
surgical or non-surgical wounds. The real incidence of MSSP and MRSP 
infections in humans may also be underestimated due to lack of awareness in 
human laboratories, as they can be misidentified as methicillin susceptible S. 
aureus (MSSA) or MRSA in routine diagnostics (van Duijkeren et al., 2011a, 
Starlander, 2014, Pottumarthy et al., 2004, Talan et al., 1989).  
 
1.4.3 Detection and differentiation of MRSP contamination and colonization   
MRSP positivity can be the result of a true MRSP colonization or of 
contamination, as well as of an MRSP infection. The term carrier is used to 
describe an individual colonized with MRSP. Colonization is the presence, 
growth and multiplication of MRSP in one or more body sites without 
observable clinical signs or immune reaction. The word contamination is used 
as when the word is used in everyday life; bacteria contaminating a dog can 
easily be washed off.  The term infection is used to describe a condition where 
MRSP has invaded a body site, is multiplying in body tissue, and is causing 
clinical manifestations of disease (van Duijkeren et al., 2011a). Both animals 
and humans can be contaminated, colonized or infected with MRSP (van 
Duijkeren et al., 2011a).  
Only a few longitudinal studies of MRSP involving repeated cultures of the 
same individuals have been published (Bergstrom et al., 2012, Laarhoven et 
al., 2011, Windahl et al., 2012). Most studies on MRSP are one-point studies 
with only one sample per individual, and it is unclear if the investigated dogs 
were colonized persistently or if they were contaminated with MRSP. 
Furthermore, studies investigating carriage of MSSP are also scarce (van 
Duijkeren et al., 2011a, Bannoehr and Guardabassi, 2012). In a review by 
Bannoehr and co-workers (Bannoehr and Guardabassi, 2012), the authors 
found only three longitudinal studies on MSSP carriage in healthy adult dogs. 
In two of these, carriage was found to be persistent (Saijonmaa-Koulumies and 
Lloyd, 2002, Cox et al., 1988). Hartman and co-workers found persistent 
carriage to be associated with higher numbers of MSSP at the colonization site 
(Hartmann et al., 2005). Bannoehr and co-workers concluded that longitudinal 
studies using appropriate sampling schemes and up-to-date methods for 
identification of MSSP are needed to classify carriage patterns as persistent 
carriage, intermittent carriage and non-carriage (Bannoehr and Guardabassi, 
2012). 
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As MRSP positivity can be either the result of a true MRSP colonization or 
of contamination and as knowledge of long-term carriage of MRSP to date is 
limited, it is difficult to certifiably discriminate between the two. Even when 
MRSP is found in repeated cultures over time from the same dog, continuous 
carriage as opposed to intermittent carriage with reinfection is difficult to prove 
in field studies. In fact, in the majority of studies on MRSP in dogs, it is 
unclear if dogs are colonized persistently or if they were only transiently 
carrying the bacterium (van Duijkeren et al., 2011a, van Duijkeren et al., 
2011b, Laarhoven et al., 2011). It has been suggested that as perineum is 
thought to be a primary colonization site for MSSP, MRSP positive cultures 
from perineal samples could be interpreted as colonization of the sampled dog 
being likely, but studies investigating this further are so far lacking (Devriese 
and De Pelsmaecker, 1987, van Duijkeren et al., 2008, van Duijkeren et al., 
2011a).  
Various DNA-based techniques have been used in strain typing of MRSP in 
surveillance and investigations of outbreaks. Pulsed-field gel electrophoresis 
(PFGE) is a highly discriminatory methods for bacterial typing of genetic 
relatedness and has generally been the preferred method, or included among 
other methods, when comparing MRSP, and MSSP,  isolates cultured within 
dog families, households and veterinary clinics, including samples from 
persons and environmental samples. Similar or indistinguishable PFGE 
patterns are interpreted as persistent carriage, or transmission of the same clone 
between dogs, persons and the environment in respective household or clinic 
(Guardabassi et al., 2004a, Soedarmanto et al., 2011, Zubeir et al., 2007, van 
Duijkeren et al., 2008, Paul et al., 2012, Loeffler et al., 2007, van Duijkeren et 
al., 2011a, Bannoehr and Guardabassi, 2012). Still, PFGE may lack the 
resolution needed to discriminate within a single clone in an outbreak or 
transmission within a household (Goering, 2010). For example, the clone 
ST71-t02-SCCmedII-III has shown a similarity of 80% or more on both a 
national and European level when compared using PFGE (Perreten et al., 2010, 
Ruscher et al., 2010, Borjesson et al., 2012). 
As most studies on MRSP are one-point prevalence studies, to what extent 
genetic changes occur over time within a carrier is unclear. Notably, a high 
variability of PFGE patterns among MSSP isolates from both healthy and 
infected dogs has been reported (Fazakerley et al., 2010). Genotypic shifts 
have also been observed in MSSP isolates from persistently colonized dogs, 
and differences in antimicrobial susceptibility phenotypes may exist among 
strains isolated from different anatomical sites of the same dog (Hartmann et 
al., 2005, Bannoehr and Guardabassi, 2012). 
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Studies involving environmental sampling of households with MRSP 
positive animals have shown widespread contamination of the environment 
(van Duijkeren et al., 2011b, Laarhoven et al., 2011). The majority of MRSP 
positive environmental samples in these studies were from areas with physical 
contact with the index case, such as the feeding and sleeping place, indicating 
that physical contact is an efficient way of MRSP transmission. The bacteria 
were however also found in sites where there was little or no physical contact 
with the index case or contact pets (e.g. the floor underneath the sofa), 
indicating that dust particles (e.g. hairs, epithelial cells) carry MRSP to those 
sites. Duijkeren and co-workers found that it was more common for 
environmental samples to be positive in households in which the index case 
was MRSP positive than if the index dog was negative. Households where the 
index case still had a clinical MRSP infection had even more positive 
environmental samples (van Duijkeren et al., 2008, Laarhoven et al., 2011). 
There are currently no guidelines on when, or if, a dog can be declared a 
non-carrier of MRSP. The risk of MRSP carriage being present, but not 
detected through sampling is unknown. Reference- or “gold” standards for 
screening of MRSP in animals are lacking both regarding laboratory 
procedures and what sample sites should be used (Beck et al., 2012, van 
Duijkeren et al., 2011a).  
Sampling of multiple body sites, and relevant sites, i.e. sites where MRSP is 
most likely found, is key in increasing detection sensitivity (Laarhoven et al., 
2011, Paul et al., 2012, Rubin and Chirino-Trejo, 2011). A minimum of both a 
nasal and rectal or perineal swabs has been recommended when screening for 
MRSP or MSSP (Weese and van Duijkeren, 2010, Rubin and Chirino-Trejo, 
2011).  
Published data on comparison of relative prevalence of positive MRSP 
cultures between various sample sites in dogs screened for MRSP carriage are 
scarce. Various combinations of sample sites have been used, including nose 
and perineum, or nose, perineum and infected sites, or nose, perineum and 
skin, with or without pooling of samples. The most commonly reported site of 
MRSP colonization in dogs is the nose and the anus, but these are also the most 
commonly tested sites (van Duijkeren et al., 2011a, Weese and van Duijkeren, 
2010, Bergstrom et al., 2012, Hanselman et al., 2009, Nienhoff et al., 2011, 
Beck et al., 2012).  
MSSP is known to colonize canine skin, hair follicles and coat, but in 
particular mucocutaneous sites, such as the nose, mouth and anus and the 
conjunctival sac. The nares, oral cavity and anal mucosa have been postulated 
to be the source of the staphylococcal population that colonizes the skin 
(Devriese and De Pelsmaecker, 1987, Beck et al., 2012). Bannoehr and co-
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workers reviewed published data on MSSP carriage in dogs and approximated 
the reported carriage rates per body sites to be as follows (ranges in 
parenthesis: nose: 31% (16-64%), mouth: 57% (42-74%), groin: 23% (16-
38%), perineum-rectum 52% (28-72%) (Bannoehr and Guardabassi, 2012). 
The authors concluded that, in contrast to S. aureus in humans, where nasal 
swabs are routinely used for screening purposes, canine carriers of S. 
pseudintermedius are most reliably be identified by swabbing both the oral 
mucosa and the perineum.  The authors also pointed out that the hygiene and 
social behaviour patterns of dogs differ from humans, and frequent exposure 
and promiscuous exchange of this bacterium is likely in the dog population. 
 
1.4.4 Risk factors for MRSP colonization and infection 
Studies on the risk factors for MRSP colonization or infection are scarce, but 
medical treatment or antimicrobial therapy, skin lesions or wounds and 
symptoms of infection including dermatitis and veterinary visits or 
hospitalization have in various studies been associated with an increased risk of 
MRSP colonization or infection in dogs (Lehner et al., 2014, van Duijkeren et 
al., 2008, Bergstrom et al., 2012, Zubeir et al., 2007, Morris et al., 2010, 
Nienhoff et al., 2011, Sasaki et al., 2007a, Weese et al., 2012, Eckholm et al., 
2013). 
Several studies have found antimicrobial treatment to be a risk factor for 
MRSP infection (Eckholm et al., 2013, Weese et al., 2012, Gronthal et al., 
2014). Studies that have not detected an association between treatment and 
presence of MRSP include one study on prevalence of MRSP from skin and 
carriage sites of dogs after treatment (Beck et al., 2012) and a case-control risk 
factor study of MRSP infection in dogs and cats (Lehner et al., 2014). Lehner 
and co-workers suggested that lack of proven association could be due to 
strain-specific variation or the longer time window for antimicrobial therapy in 
the study; analysis of more recent antimicrobial therapy might have shown a 
stronger effect on MRSP selection as adaption to different niches may occur 
more rapidly than anticipated (Lehner et al., 2014). Both Lehner and Beck also 
suggested that as an alternative explanation, MRSP is as well adapted to canine 
skin as MSSP. If so, selective pressure is of no benefit for MRSP (Lehner et 
al., 2014, Beck et al., 2012).  
However, as mentioned above, logical hypotheses and biological data on 
antimicrobial therapy selecting for resistant bacteria support a risk of 
antimicrobial therapy selecting for MRSP carriage and infection. The normal 
bacterial skin flora occupies microbial niches and inhibits colonization by 
invading organisms, and it has been shown that antimicrobial treatment can 
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enable survival and colonization of pathogenic bacteria resistant to the 
antimicrobial in question by suppressing part of this flora (Muller, 2001, 
Graffunder and Venezia, 2002, Ogeer-Gyles et al., 2006c).  
The risk for facilitating bacterial growth and thereby prolonging clinically 
apparent infections by prescribing antimicrobials should also not be 
overlooked. Beck and co-workers found that 62% of MRSP positive dogs with 
clinical bacterial pyoderma were still MRSP positive after clinical resolution. 
In addition, 28% of dogs with bacterial pyoderma that previously had tested 
negative for MRSP were found to be MRSP positive after antimicrobial 
treatment. The authors concluded that the selection pressure exerted by 
antimicrobial therapy facilitated colonization of MRSP in the previously 
MRSP negative dogs. Furthermore, the study results suggested that systemic 
treatment with an antimicrobial effective in vitro against MRSP is unlikely to 
be effective for decolonization therapy (Beck et al., 2012). 
Systemic glucocorticoid therapy has also been suspected to predispose for 
MRSP carriage in dogs, although presence of skin disease might have 
influenced the association (Nienhoff et al., 2011). Chronic skin disorder has 
been reported to be a risk factor for acquisition of MRSP. Factors that may 
contribute to the detected association include long-term antimicrobial pressure 
and frequent veterinary visits, as well as the changes in the skin (Griffeth et al., 
2008, Huerta et al., 2011).  
Staphylococcus pseudintermedius carriage rates have been shown to be 
higher in dogs with atopic dermatitis compared to healthy individuals. 
Furthermore larger populations of S. pseudintermedius have been found in 
dogs with dermatitis, compared to clinically normal dogs (Bannoehr and 
Guardabassi, 2012, Fazakerley et al., 2009, Lloyd D.H. et al., 1991, Harvey 
RG, 1998). In human medicine, the risk of becoming colonised and carry 
MRSA on the skin, (and thereby the risk of spreading the bacteria to other 
individuals) has been shown to increase with such skin changes (Higaki et al., 
1999, Gong et al., 2006). 
As mentioned above, healthcare-associated infections with MRSP have been 
described, and hospitalization as well as surgical invention has been suspected 
to increase the risk of MRSP colonization or infection in dogs. Contamination 
of veterinary hospital environments, as well as of staff, with MRSP has been 
documented. Investigations have found MRSP isolates that were 
indistinguishable when compared by PFGE from dogs, cats and the hospital 
environment they have been visiting, suggesting nosocomial transmission 
(Zubeir et al., 2007, van Duijkeren et al., 2008).  
In a study by Bergström and co-workers, MRSP was detected in the 
hospital environment and from hospitalized dogs treated surgically, but not 
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from healthy dogs visiting the same environment (Bergstrom et al., 2012). 
There was also a significant increase in the number of dogs carrying MRSP 
after hospitalization compared to admission. Antimicrobial treatment was 
considered to be a potential contributing factor, as well as surgical stress, 
anesthesia, and change in environment. Grönthal and co-workers described a 
nosocomial outbreak of MRSP in a small animal hospital. The cases of MRSP 
infections were spatially and temporally connected. All infections were 
surgical site infections or other infections which appeared after prolonged 
hospital treatment, and none of the MRSP positive patients had evidence of 
MRSP on admission. The cumulative number of days spent in the intensive 
care unit or in the surgery ward was associated with an increased risk of MRSP 
positivity in hospitalized dogs (Gronthal et al., 2014). It has been suggested 
that veterinary hospitals and practices play an important, or even central role in 
the dissemination of MRSP in the general dog population. It is possible that 
MRSP initially emerges as more of a healthcare associated pathogen than a 
community associated pathogen. As colonized and infected patients becomes 
more prevalent in the community, the risk of community-acquired MRSP 
increases. Preventative measures towards spread of MRSP in veterinary 
healthcare environments should therefore be considered a critical cornerstone 
in combating the increase of this multidrug resistant bacterium (van Duijkeren 
et al., 2011a, Guardabassi and Prescott, 2015, Guardabassi, 2012, Weese and 
van Duijkeren, 2010, Lehner et al., 2014). 
Transmission from MRSP infected or MRSP colonized dogs to healthy 
contact dogs living in the same household has been described in two recent 
studies, of which one was a longitudinal study and the other a one-point 
prevalence study (Laarhoven et al., 2011, van Duijkeren et al., 2011b). 
Information on horizontal transmission of MSSP between adult dogs is also 
scarce. Puppies have been shown to become colonized with MSSP soon after 
birth as a result of vertical transmission from the dam, equivalent to the 
mother-to-infant transmission of S. aureus seen in humans (Saijonmaa-
Koulumies and Lloyd, 2002, Paul et al., 2014). In the study by Paul et al, both 
long-term persistence of strains transmitted vertically, and frequent sharing of 
strains between offspring belonging to the same litter was shown (Paul et al., 
2014).  
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2 Aims  
The overall aims of this thesis were to gain knowledge of bacterial infections in 
dogs in Sweden with special reference to urinary tract infections, surgical site 
infections and their antimicrobial susceptibility patterns, and of carriage of 
methicillin-resistant Staphylococcus pseudintermedius (MRSP). The results 
were intended to aid in choice of antimicrobial treatment of canine urinary tract 
infections and surgical site infections, and in designing recommendations on 
prevention and control of carriage of MRSP. 
 
The specific aims were to: 
 
 Investigate the relative presence of bacterial pathogens in urinary tract 
infections and surgical site infections in dogs and factors that might 
influence the culture results. 
 Investigate susceptibility of bacterial isolates from urinary tract infections 
and surgical site infections. Multidrug resistant phenotypes, extended 
spectrum cephalosporin resistance in Enterobacteriaceae, MRSP and 
methicillin-resistant Staphylococcus aureus (MRSA) were of particular 
interest. 
 Investigate if dogs clinically infected with MRSP can become 
asymptomatic long-term carriers, and investigate factors that might 
influence length of such carriage.  
 Investigate potential MRSP carriage in contact dogs within multidog 
households where clinical MRSP infection has been diagnosed in one or 
several dogs. 
 Collect and evaluate data relevant for development of sampling strategies 
for asymptomatic MRSP carriage in dogs.  
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3 Materials and Methods  
 
3.1 Summary of study design 
 Paper I and II are observational studies, where samples from clinical 
infections were analysed. 
 
 Paper III and IV are longitudinal prospective studies where dogs diagnosed 
with a methicillin-resistant S. pseudintermedius (MRSP) infection were 
sampled repeatedly for possible carriage of MRSP, regardless of whether 
clinical symptoms of infection were present or not.  
3.2 Study material  
 
3.2.1 Samples 
In study I and II samples from clinical infections were analysed. 
In study I urine samples collected from dogs with clinical signs of urinary 
tract infection submitted by attending veterinarians to SVA (National 
Veterinary Institute, Sweden) for culture and susceptibility testing during a 
study period of ten months (March-December 2009) were investigated. The 
samples originated from four small animal referral hospitals, ten small animal 
clinics and 115 mixed veterinary practices. In total 623 samples from as many 
individual dogs yielded positive pathogenic growth. Forty-eight additional 
positive samples from already included dogs were evaluated separately. The 
samples were submitted as urine sent in a sterile container (19%), bacterial 
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swabs dipped in urine (13%), pre-incubated cultures on dipslides (42%) or agar 
plates (26%).  
In study II four animal referral hospitals and three small animal clinics sent 
samples from all detected SSI in canine patients at time of diagnosis to SVA 
for culture and susceptibility testing during three years (April 1, 2008 - April 
29, 2010). In total 157 cases of SSI where the samples yielded positive 
bacterial growth from a wound infection clinically diagnosed within a month 
after surgery were included. All samples were submitted as bacterial swabs. 
 
In study III and IV, dogs diagnosed with an MRSP infection were sampled 
repeatedly for investigation of carriage of MRSP, regardless of whether clinical 
symptoms of infection were present or not after time of inclusion sample. A 
selective enrichment culture aimed at detecting MRSP was used. 
In study III, 31 dogs diagnosed with an MRSP infection were sampled with 
intervals of at least six weeks until two consecutive negative results were 
obtained or until at least five months after the inclusion sample. Five body sites 
were sampled using bacterial swabs: nostrils, pharynx, perineum, the corner of 
the mouth and, when present, wounds.  
In study IV, 11 dogs from four unrelated multiple dog households where 
one or two dogs had been diagnosed with an MRSP infection were included. 
All dogs in each family group were sampled simultaneously with 1-7 months 
intervals, during 7 (one family group) or 12- 15 months (three family groups). 
Four body sites were sampled using bacterial swabs: pharynx, perineum, the 
corner of the mouth and, when present, wounds.  
 
3.2.2 Sample analyses 
In study I and II routine microbiological culture and susceptibility testing of 
the submitted sample material was performed (CLSI, 2008, G.R. Carter., 1990, 
Barrow, 1993, Quinn P.J., 2011). In study I, a screening for presence of 
Enterobacteriaceae resistant to extended-spectrum cephalosporins (ESC) was 
performed through additional culture of the submitted sample material on 
selective screening media. 
In study III and IV, a selective enrichment culture for MRSP was used. In 
study III, isolates from the last positive sample occasion was compared to 
either the inclusion sample (n = 21) or the first sample collected after inclusion 
(n = 5) by pulsed-field gel electrophoresis (PFGE). In study IV, all cultured 
MRSP isolates were genotypically characterized and compared using whole 
genome sequencing 
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3.2.3 Collected information and data included in the analyses  
In study I, information was collected from recordings in the laboratory 
database based on the submission form submitted to SVA together with the 
samples.  
Data included in the multivariable logistic regression analyses of the results 
from the bacteriological culture and antimicrobial susceptibility testing were: 
whether the samples were sent in as pre-incubated cultures or not, whether the 
cultures were contaminated or pure, and if the samples originated from referral 
hospitals, small animal clinics or mixed veterinary practices. 
In study II, information was collected from a questionnaire completed by 
the attending clinician at time of sampling. Data included in the multivariable 
logistic regression analyses of the results from the bacteriological examination 
and antimicrobial susceptibility testing were: submission origin (which animal 
hospital or from a small animal clinic), duration of hospitalization, 
antimicrobial treatment, category of surgical procedures (clean, clean-
contaminated, contaminated or dirty), depth of infection (superficial skin 
infections or deeper), and whether the culture was mixed with two pathogens 
or not.  
 
In study III and IV, information was collected from a questionnaire completed 
by the attending clinician at time of sampling, as well as from the included 
dogs’ medical records.  
Data compiled and included in the multivariable logistic regression analyses 
of MRSP carriage over time were in study III: gender (female or male), age (≤ 
6 years or older), diagnosis at time of clinical infection i.e. of the inclusion 
sample (dermatitis, surgical site infection, or infection/trauma), presence of 
dermatitis or wounds during the study, and time of systemic antimicrobial 
treatment. Data on dermatitis and presence of wounds were also included in 
evaluation of the relative number of MRSP positive cultures yielded from each 
sample site. Data on contacts with other dogs was compiled but not included in 
the analyses. 
In study IV information on medical treatments, veterinary visits, skin 
lesions or wounds and symptoms of infection including dermatitis, as well as 
contacts with dogs outside of the household was collected.  
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4 Results and discussion 
 
4.1 Bacterial growth in urinary tract infections and surgical site 
infections 
 
4.1.1 Bacterial growth in the urinary samples  
Seven different urinary pathogens were identified in 623 positive cultures with 
a specific urinary pathogen. Escherichia coli was the most prevalent, identified 
in 429 (68.9%) of the samples, followed by S. pseudintermedius (9.6%),         
P. mirabilis (8.8%), beta haemolytic Streptococcus spp. (5.6%), Enterococcus 
spp. (3.7%), Klebsiella spp. (1.8%) and S. aureus (1.6%). 
Forty-eight positive cultures were repeated samples from dogs already 
included in the study. The same pathogen was isolated on both occasions for 
all of the dogs. The bacteria isolated were E. coli (81.2 %), S. 
pseudintermedius (6.3%), P. mirabilis (6.3%), Klebsiella spp. (4.2%), and 
Enterococcus spp. (2.0%).  
The number of samples excluded due to either no growth, insignificant non-
specific growth or growth of contaminants that prohibited further confirmation 
was 338 (35%) of the 1042 samples submitted.  
There was a higher probability of finding S. pseudintermedius in pre-
incubated samples (n = 49) compared to non-incubated samples (n=20) 
(OR=2.2; P = 0.019). The ten S. aureus isolates were all found in pre-incubated 
samples. The probability of finding E. coli was lower (OR=0.6; P=0.005) in 
contaminated cultures (n = 155) than in pure cultures (n = 274).  
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No association was found between the three submission categories (referral 
hospitals, small animal clinics or mixed veterinary practices) and relative 
prevalence of the respective bacterial species.  
 
4.1.2 Investigation of influences on the culture and susceptibility results of the 
urinary tract infections 
The seven urinary pathogens isolated in study I are the bacterial pathogens 
most frequently associated with UTI in dogs, and E. coli being the most 
prevalent with staphylococci in second place is also reflected in previous 
studies (Seguin et al., 2003, Bartges, 2004, Ling et al., 2001, Ogeer-Gyles et 
al., 2006a). 
A positive culture with known bacterial pathogens was an inclusion criteria 
and a prerequisite for the diagnosis of UTI. Samples that yielded either no 
growth or only insignificant non-specific growth where therefore not further 
investigated in either study I or II, and it was the relative prevalence of each 
detected bacterial pathogen within the subgroup positive cultures that was 
investigated, not percentage positive cultures of all submitted samples.  
Cystocentesis was the recommended method for collection of urine samples 
for bacteriological culture from SVA to all veterinarians submitting samples 
during the study period. However, approximately 40% of all samples were 
contaminated. Contamination of the urine samples indicate that other methods 
of sample collection were common. This was true also for samples from 
referral hospitals, known to have resources for cystocentesis and 
implementation of routines for collection of urine samples. As contaminated 
samples were common, the relative prevalence of the different pathogens was 
compared between contaminated and pure growth, both of which indicates the 
quality of collection- and handling procedures of the individual sample. For all 
but one bacterial species, there was no significant difference in prevalence 
between these two categories. The exception was E. coli, which was found 
significantly more often in pure culture, which indicates that the relatively high 
prevalence of E. coli in the material was not due to misinterpretation of 
contaminated samples. 
To investigate the effect of sampling method and subsequent handling of 
samples including transport and transport medium on number of positive 
cultures (the susceptibility of the testing), a different study setup is needed, and 
the possible influence of collection method and handling of the samples on 
bacterial growth in study I could not be fully evaluated. The information was 
not included in the submission forms and although many of the referring 
veterinary clinics and hospitals had in-house recommendations for how to 
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collect and handle samples it was not possible to retrospectively retain reliable 
data regarding to which extent those recommendations had been followed. A 
retrospective investigation to clarify sample methods during the writing of 
study I was aborted as the information was decided not to become rigorous 
enough for statistical purposes. However, altogether including the results of the 
investigation of associations between findings of the isolated uropathogens, 
submission and if cultures were pure or contaminated - as well as investigation 
of associations between submission categories, the material was considered to 
be representative enough for describing bacterial growth and investigating 
antimicrobial susceptibility in UTI in the included dog population. 
Choice of submitted sample material was not shown to be a major factor 
influencing the relative prevalence of bacterial species, with the exception of 
staphylococci, which were found more often in pre-incubated sample media. 
This finding supports the use of preincubated media when submitting urinary 
samples, as it lessens the risk of UTI infections with staphylococci, including 
MRSP, to go unnoticed. 
 
4.1.3 Bacterial growth in the surgical site infections 
In 37 (23%) of the positive cultures two pathogens were detected, leaving in 
total 194 pathogenic isolates from the 157 dogs included in the study. Eight 
different bacterial species were identified. Staphylococcus pseudintermedius 
was the most prevalent finding (46%), followed by beta haemolytic 
Streptococcus spp. (24%), E. coli (11%) and S. aureus (8%). The remaining 
pathogenic isolates were S. schleiferi (4%), Pasteurella multocida (3%), 
Proteus mirabilis (2%) and Pseudomonas aeruginosa (2%). 
An additional pathogen was identified in 66% of the 47 cultures positive for 
beta haemolytic Streptococcus spp., and in 30% of the 90 cultures positive for 
S. pseudintermedius. It was significantly more common to find beta haemolytic 
Streptococcus spp. than S. pseudintermedius, S. aureus, E. coli and 
Pseudomonas aeruginosa in the 37 mixed cultures (P<0.05). 
There were no associations between distribution of the isolated pathogens 
and submission category, duration of hospitalization or classification of the 
surgical procedure. Furthermore, there were no associations between any of the 
explanatory factors and whether there were two pathogens in the culture or not. 
One significant association between isolated pathogen and depth of infection 
was found. Escherichia coli was found significantly more often in deep wound 
infections than in superficial skin infections (OR = 4.7, P = 0.02). The reason 
for this finding is unknown. 
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4.1.4 Investigation of influences on the culture and susceptibility results of the 
surgical site infections 
As in study I, attending veterinarians made the initial clinical diagnosis and 
collected all samples included in study II. A written description of standardised 
sample methods was sent to the enrolled hospitals and clinics together with the 
submission form and a questionnaire. All cases were sampled with a bacterial 
swab. A positive culture with known bacterial pathogens was an inclusion 
criterion, and a prerequisite for the diagnosis SSI. During the study period, 
23% of 203 submitted samples were excluded due to the submitted samples 
yielding either no growth or only insignificant non-specific growth. 
All the bacteria cultured in the study, including those less commonly 
associated with skin disease and skin carriage, might be endogenous flora 
recently transferred to the skin at the incision site through the dogs grooming 
behaviour, or through contamination of affected tissues during surgery 
(Nelson, 2011, Weese, 2013, May, 2006, Priestnall and Erles, 2011, Turk et 
al., 2015, Nicoll et al., 2014, Summers et al., 2012, Rodrigues Hoffmann et al., 
2014, Quinn P.J., 2011, Eugster et al., 2004). Due to the possibility of 
prolonged contact with the microbiota in the healthcare environment 
influencing pathogenic growth, duration of hospitalization as well as 
submission category was recorded, but no influence on distribution of the eight 
bacterial species was shown (Wieler et al., 2011b, Bratzler et al., 2005, Nelson, 
2011, Johnson, 2002).  
As mentioned above, when evaluating SSI, an objective definition is 
desirable. This facilitates comparisons between veterinary studies, in which 
various definitions have been used for postoperative SSI (Weese, 2008c, 
Eugster et al., 2004, Nelson, 2011). In study II, The National Nosocomial 
Infections Surveillance criteria were used (Mangram et al., 1999). However, 
the standard classification of the wounds such as superficial incisional, deep 
incisional or organ/space was deemed not appropriate as, with the exception of 
the infections classified as superficial, the information attained from the 
attending veterinarians was decided not to be rigorous enough (Mangram et al., 
1999). Infections including soft- or skeletal tissue or infections in the form of 
an abscess could have been classified as deep incisional, but as only seven 
isolates originated from this category with four bacterial species represented, 
the use of only the two terms superficial skin infection and deeper infection 
was deemed more stringent.   
The National Nosocomial Infections Surveillance criteria were developed 
for surveillance of SSI in humans, and although a clear correlation between the 
four categories of surgical procedures and SSI rates has been reported in 
human medicine, it is not possible to determine either the risk of SSI to 
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develop or the source of the bacteria causing the SSI solely based on category 
of surgery (Mangram et al., 1999, Weese, 2008c, Eugster et al., 2004). 
However, the risk of an SSI being caused by an infecting agent present prior to 
surgery is increased in the dirty category, to which 18% of the 194 isolates in 
study II belonged. Furthermore, the risk of the SSI being caused by 
endogenous flora from the gastrointestinal, genitourinary or respiratory tracts 
can be expected to be lower in the clean category, as procedures where these 
body sites are opened are not included in this category (Mangram et al., 1999). 
No such correlations were found in study III. The only significant association 
between distribution of the isolated pathogen and the investigated explanatory 
factors was between growth of E. coli and depth of infection as well as with 
antimicrobial treatment during time of sampling. The reasons for these findings 
are unknown. The multifactorial nature of SSI, including critical factors such 
as adherence to aseptic principles and proper aseptic preparation and 
postoperative care in veterinary care facilities as well as in the home 
environment, complicates studies of this kind. Further studies on associations 
between individual bacterial species causing SSI and factors that can influence 
these are thus warranted.  
 
4.1.5 Influence of antimicrobial treatment on the culture and susceptibility 
results  
It has previously been stated that, as referral hospitals are more likely to have a 
higher caseload of complicated and recurrent medical and surgical cases, 
isolates can be expected to be less susceptible in samples originating from 
referral animal hospitals compared to smaller clinics. The samples included in 
study I and II were from veterinary practices with a wide geographical spread 
over the country and with both primary care facilities and referral animal 
hospitals represented. The material was thus considered representative of the 
actual dog population in the country. Interestingly, the resistance in UTI 
isolates was higher in samples originating from small animal clinics or mixed 
veterinary practices than in samples from referral animal hospitals.  
Possible associations between submission category and antimicrobial 
susceptibility patterns could not be statistically evaluated in the SSI cases, due 
to the small number of isolates with diverging resistance patterns within each 
bacterial species. 
In study I, previous and ongoing antimicrobial treatment was unknown. 
According to the Swedish Veterinary Association national guidelines for the 
clinical use of antibiotics in the treatment of dogs and cats (www.svf.se), 
culture and antimicrobial susceptibility testing should always be performed 
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when UTI is suspected in a dog. An exception is uncomplicated first-time UTI 
in young bitches. It is still possible that some dogs included in the study were 
sampled only after one or several antimicrobial treatments. However, the low 
percentage of resampled dogs correlates with previous reports of numbers of 
recurrent UTI (Ling, 1984, Norris et al., 2000, Seguin et al., 2003). 
In study II, assessment of the influence of antimicrobial treatment on 
culture and resistance was not possible as too few isolates of each bacterial 
species were from cases that had received antimicrobial treatment, and even 
fewer  from cases that had received treatment for more than one day (not only 
perioperative treatment). Notably, only twenty or less isolates were resistant to 
the agent used, which indicates that antimicrobial selective pressure on 
pathogenic growth was not significant.  
 
4.2 Antimicrobial susceptibility patterns in urinary tract infections 
and surgical site infections 
 
4.2.1 Antimicrobial susceptibility patterns in the urinary tract infections 
There were some differences in antimicrobial susceptibility patterns in the 
repeated urinary samples compared to the first sample from each dog. In six of 
the seven cultures yielding resistant E. coli, the isolates were less susceptible in 
the repeated sample than on the first sample occasion. Four isolates were 
multidrug resistant (10% of the 39 E. coli isolates). Multidrug resistance was 
present in the first isolates from the three dogs involved, but the isolates from 
the repeated samples had additional resistance to trimethoprim- 
sulphamethoxazole. In one dog, an S. pseudintermedius isolate susceptible to 
penicillin was isolated on the first, and a penicillin resistant S. 
pseudintermedius isolate on the second sample occasion. 
Comparison of susceptibility patterns between the three submission 
categories showed that the probability of finding trimethoprim- 
sulphamethoxazole resistant E. coli was higher from small animal clinics or 
mixed veterinary practices than from referral hospitals (OR=3.4; P=0.01 and 
OR=3.9; P=0.004, respectively). The probability of finding tetracycline 
resistant E. coli was higher (OR=2.5; P=0.04) for mixed veterinary practices 
than for referral hospitals. Furthermore, E. coli from mixed veterinary practices 
were more likely to be multidrug resistant than isolates from referral hospitals 
(OR=2.7; P=0.02).  
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Table 1. Antimicrobial susceptibility (% susceptible isolates) of E. coli, 
Klebsiella spp. and P. mirabilis in non-repeated urinary samples. The number 
of samples is shown inside brackets.   
 
Table 1.  
Antimicrobial Escherichia coli 
(n=429) 
Klebsiella spp. 
(n =11) 
Proteus mirabilis 
(n=55) 
 % S % S % S 
Ampicillin 87.9 0.0 90.9 
Amoxicillin/ Clavulanic 
acid 
87.2 72.7 94.5 
Cefotaxime 99.8 100 98.2 
Gentamicin 94.9 90.9 83.6 
Enrofloxacin 97.9 90.9 96.4 
Tetracycline 92.1 100 5.5 
Trimethoprim/ 
Sulphametoxazole 
92.3 90.9 89.1 
Nitrofurantoin 
 
98.4 27.3 9.1 
 
 
 
 
 
 
 
 
 
 
 
52 
 
Table 2. Antimicrobial susceptibility (% susceptible isolates) of S. 
pseudintermedius, S. aureus, beta haemolytic streptococci and enterococci in 
non-repeated urinary samples. The number of samples is shown inside 
brackets.   
Table 2.  
Antimicrobial Staphylococcus 
pseudintermedius 
(n=60) 
Staphylococcus 
aureus 
(n=10) 
Beta-
hemolytic 
streptococci 
(n=33) 
Enterococci 
(n=55) 
 % S % S % S % S 
Penicillin  10.0 30.0 100 NR 
Ampicillin 10.0 30.0 NR 87.0 
Amoxicillin 
/Clavulanic acid 
96.7 100 100 82.6 
Cephalothin 98.3 100 100 13.0 
Oxacillin NRa 100 - - 
Gentamicin 98.3 100 0.0 30.4 
Erythromycin 86.7 100 NR 34.8 
Enrofloxacin 98.3 100 15.2 47.8 
Tetracycline 66.7 90.0 63.6 65.2 
Trimethoprim/ 
Sulphametoxazole  
95.0 100 100 87.0 
Nitrofurantoin 
 
100 100 100 82.6 
aNot relevant (NR) as breakpoints used to define isolates as susceptible (BP-S) is below the range of concentrations 
tested.
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4.2.2 Antimicrobial susceptibility patterns in the surgical site infections 
The majority of the isolates (68%) were from cases that had not received 
antimicrobial treatment prior to sampling. Also, 68% of the 62 isolates in the 
treated group were susceptible to the antimicrobial used. Seventeen percent of 
all 194 isolates were from cases sampled during ongoing antimicrobial 
treatment.  
Escherichia coli was significantly more often found in samples collected 
during antimicrobial treatment than the other pathogens (OR=4.7, P=0.002). 
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Table 3. Antimicrobial susceptibility of isolated pathogens in the surgical site infections presented as the percentage of susceptible 
isolates (%S). 
Table 3 
   Antimicrobials testeda 
   AMP PEN CEP OXA CTX ERY CLI ENR GEN TET T-S 
Staphylococcus pseudintermedius 
n=90 
% S 20.0 20.0 95.6 NRb NRc 76.7 NR b 94.4 93.3 73.3 75.6 
Staphylococcus aureus 
n=15 
% S 20.0 20.0 100 100 NRc 100 NRb 100 100 93.3 93.3 
Staphylococcus schleiferi 
coagulans 
n=7 
% S 14.3 14.3 100 NRb NRc 71.4 85.7 100 100 85.7 100 
beta haemolytic Streptococcus spp.  
n=47 
% S NRb 100 100 NRc NRc NRb NRb 17.0 0.0 66.0 100 
Escherichia coli 
n=20 
% S NRb NRc 5.0 NRc 95.0 NRc NRc 100 100 80.0 90.0 
Pasteurella multocida 
     n=6 
% S NRc 100 100 NRc NRc NRc NRc 100 100 100 100 
 
aAmpicillin (AMP), penicillin (PEN), cephalothin (CEP), oxacillin (OXA), cefotaxime (CTX), erythromycin (ERY), clindamycin (CLI), enrofloxacin (ENR),gentamicin (GEN),tetracycline 
(TET),trimethoprim-sulfamethoxazole(T-S).  
bNot relevant (NR) as breakpoints used to define isolates as susceptible (BP-S) is below the range of concentrations tested.  
cNot relevant (NR) as no BP-S is available
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4.2.3 Multidrug resistance, ESC-resistance, detection of MRSA and MRSP in 
the urinary tract infections and surgical site infections 
 
Multidrugresistance 
Overall, multidrug resistance was rare, and all MDR isolates were susceptible 
to at least one antimicrobial relevant for the species and for the treatment of the 
investigated infections. 
An MDR pathogen was detected in approximately 4% of all UTI cases, and 
in 19% of all SSI cases. 
MDR was most common in S. pseudintermedius, as 10% (n=6) and 26% 
(n=23) of the isolates were MDR in study I and II, respectively. Approximately 
4% (n=17) of E. coli isolates in study I were MDR. In study II, none of the in 
total 21 E. coli isolates were MDR. 
One of the P. mirabilis isolates (2%) and two enterococcus isolates (9%) 
were MDR in study I, and in study II one beta-haemolytic Streptococcus spp. 
isolate had an MDR phenotype. 
 
Resistance to extended-spectrum cephalosporins 
Two isolates with a transferable gene conferring ESC resistance were detected 
in study I and II. In study I, one E.coli isolate carried the blaCMY-2 gene and in 
study II one E. coli isolate carried the blaCTX-M-1 gene. In addition one P. 
mirabilis isolate from study I produced AmpC beta-lactamase but was not 
tested for genotype. 
Four of the ESC-positive isolates from UTI samples were detected in the 
screening culture, but not in the routine culture; two E. coli isolates and two 
Enterobacter isolates (Enterobacter cloacae and Enterobacter aerogenes). The 
two latter were most likely classified as contaminants in the routine culture of 
the samples. One P. mirabilis isolate diagnosed in routine culture was not 
detected on the screening agar. The small number of isolates preclude 
statistical assessment of potential benefits of the additional use of the selective 
screening culture for detection Enterobacteriaceae resistant to ESC in canine 
urinary samples. 
 
Methicillin-resistant Staphylococcus aureus 
No MRSA isolates were detected.  
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Methicillin-resistant Staphylococcus intermedius 
Less than 3% (n=4) of S. pseudintermedius isolates in study I and II were 
confirmed as mecA carriers; 2% of the 60 S. pseudintermedius isolates in study 
I and 1% of the 90 S. pseudintermedius isolates in study II. 
 
4.2.4 Interpretation of the antimicrobial susceptibility results from the 
investigated urinary tract infections and surgical site infections 
 
In both studies, antimicrobial susceptibility was tested according to the 
standards of the Clinical and Laboratory Standards Institute (CLSI), using 
CLSI clinical minimum inhibitory concentrations (MIC) breakpoints (BPs) 
(CLSI, 2008). Although interpretive criteria might change, the use of these 
methods and breakpoints facilitates comparison of the results to future study 
results, and the results can provide a basis for future monitoring of 
antimicrobial resistance. The concentration ranges of the test panels used 
(VetMIC, SVA, Uppsala, Sweden) did not allow interpretation of MICs by 
CLSI BPs for all combinations of antibacterial and bacterial species. Only 
isolates susceptible according to CLSI BPs were included in the susceptible 
category, and when MDR was evaluated, all intermediately susceptible isolates 
were included in the resistant category. 
Nitrofurantoin, gentamicin, and the combination trimethoprim- 
sulfamethoxazole were not intended to represent resistance towards other 
clinically relevant agents used for dogs. Furthermore, susceptibility to 
cefotaxime was tested as an indicator of ESC-resistance in E. coli, Klebsiella 
spp. and P. mirabilis isolates, although licensed products for dogs are 
available, for which the susceptibility testing is relevant (third-generation 
cephalosporins). Oxacillin was included as an indicator for methicillin 
resistance in staphylococci. Enrofloxacin was used as a representative for 
fluoroquinolones commonly used in dogs, although not for more recently 
developed fluoroquinolones such as pradofloxacine. Tetracycline susceptibility 
results were regarded as representative also for doxycycline.  
Erythromycin has been used for treatment of staphylococcal pyoderma in 
dogs. It is also considered a relevant choice for treatment of intestinal 
infections with Campylobacter spp., and as a possible second choice in for 
example infections caused by anaerobic bacteria in dogs (Frank and Loeffler, 
2012, Giguère et al., 2006, Noli and Boothe, 1990). Erythromycin is currently 
not approved for use in dogs in Sweden, and it was not intended to represent 
other macrolides, some of which are mainly used in large animal practice. 
However, the proportion of clindamycin susceptible staphylococcal isolates 
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and erythromycin susceptible staphylococcal isolates can be expected to be 
similar. 
Clindamycin is a first-line antimicrobial for treatment of for example 
staphylococcal pyoderma (Giguère et al., 2006, Hillier et al., 2014). The CLSI 
BPs for clindamycin were outside of concentration ranges of the test panels 
used. However, although resistance in staphylococci can develop to 
lincosamides alone, lincosamid resistant strains are generally resistant to 
macrolides as well. The so called MLS-, or MLSB resistance phenotype 
(macrolide, lincosamide and streptogramin group B antibiotics resistance) can 
be either constitutive resistance, where bacteria show high-level resistance to 
all MLS antimicrobials, or inducible cross-resistance, in which the bacteria are 
resistant to macrolides but initially fully susceptible to clindamycin. Routine 
antimicrobial susceptibility testing of clindamycin can detect constitutive MLS 
resistance but fails to detect inducible resistance. Treatment failure can be 
expected when clindamycin is used for these strains. Simultaneous 
susceptibility testing to erythromycin is an aid in detecting such inducible 
clindamycin resistance, that should be suspected in isolates that in vitro are 
erythromycin resistant but clindamycin susceptible (Cain, 2013, Gold and 
Lawhon, 2013, Gortel, 2013). 
The results of the susceptibility testing to benzylpenicillin (penicillin G) are 
also applicable to phenoxymethyl-penicillin (penicillin V). In a clinical 
situation this is also the case for the results of ampicillin and amoxicillin. 
Cephalotin was used as a representative for all first generation cephalosporins. 
All staphylococci were tested for beta-lactamase- (penicillinase) production 
which, if present, renders the isolates resistant to penicillin, ampicillin and 
amoxicillin (aminopenicillins). Staphylococcal isolates susceptible to the tested 
cephalosporins and resistant to aminopenicillins through beta-
lactamaseproduction, were considered to most likely be susceptible to the 
combination amoxicillin-clavulanic acid, as the clavulanic acid inactivates the 
beta-lactam enzymes. 
In this thesis, the definition for phenotypic susceptibility testing of MDR 
recommended by Schwarz and co-workers was utilized; acquired resistance to 
three or more classes of antimicrobial agents (Schwarz et al., 2010). As 
described above, intermediately susceptible isolates were also included in the 
resistance category. 
For the classification of MDR in E. coli, Klebsiella spp., and P. mirabilis 
isolated from UTI samples, ampicillin and amoxicillin-clavulanic acid were 
considered one antimicrobial class. For the classification of staphylococci, 
streptococci and enterococci, ampicillin, amoxicillin-clavulanic acid, 
cephalothin and penicillin were considered one antimicrobial class. 
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Antimicrobials not included in the classification of MDR due to inherently 
low susceptibility of the bacterial species included: for Klebsiella spp.; 
ampicillin and nitrofurantoin, for P. mirabilis; nitrofurantoin and tetracycline, 
and for streptococci enrofloxacin and gentamicin. Enterococci have 
constitutively low susceptibility to several of the antimicrobials studied, and 
only ampicillin, tetracycline, trimethoprim-sulfamethoxazole and 
nitrofurantoin were considered in the evaluation of MDR in this species 
(Kristich et al., 2014, Ossiprandi et al., 2008, Hollenbeck and Rice, 2012). 
 
4.2.5 Antimicrobial treatment choices for treatment of the urinary tract 
infections and surgical site infections, a summary 
 
Excluding the 4% MDR infections where still at least one relevant 
antimicrobial relevant for the bacterial species and respective infection was 
available, there were several relevant first-line treatment options in all the 
investigated UTI and SSI.  
Susceptibility to first-line antimicrobials for UTI caused by E. coli was 
approximately 90-100%. In approximately half (56%) of all UTI, the causative 
pathogen was E. coli isolates susceptible to all the tested antimicrobials 
intended for clinical use (ampicillin, amoxicillin-clavulanic acid, trimethoprim-
sulfadiazine, tetracycline, enrofloxacin, and nitrofurantoin).  
Susceptibility rates were high also in the ten per cent caused by either P. 
mirabilis or Klebsiella spp. Susceptibility to penicillin and ampicillin was 
uncommon in the six percent of UTI caused by S. pseudintermedius. However, 
as susceptibility rates to amoxicillin-clavulanic acid, enrofloxacin, and 
nitrofurantoin were high not only in staphylococcal isolates but also in beta-
haemolytic streptococci, and enterococci, several relevant treatment options 
were available also in the UTI caused by a gram-positive pathogen. 
Excluding the 23% of the SSI cases where an MDR S. pseudintermedius 
isolate, including MRSP was detected, several first-line antimicrobials were 
available for treatment of the SSI. This includes cases where more than one 
pathogen was detected. Except for beta-lactamase resistance to 
aminopenicillins in staphylococci, the isolated pathogens from the SSI cases 
were mostly without acquired resistance.  
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Antimicrobial susceptibility of key pathogens, an overview 
 
 Escherichia coli  
Susceptibility to first-line antimicrobials for E.coli infections in UTI was 
approximately 90-100%. Susceptibility rates for E. coli isolated from SSI cases 
were 80% to tetracycline and 90-100% for trimethoprim-sulfadiazine, 
tetracycline and enrofloxacin.  
Except for treatment of UTI, a low susceptibility to ampicillin and first 
generation cephalosporins is expected for E.coli, which is reflected in only 5% 
of the SSI isolates being susceptible to first generation cephalosporins. 
Although the BPs for ampicillin were outside of concentration ranges of the 
test panels used for the SSI cases, the high ampicillin MIC50 indicates a large 
proportion of ampicillin resistant isolates. 
Antimicrobials either not tested, or results not shown because the 
breakpoints used to define isolates as susceptible (BP-S) were below the range 
of concentrations tested, include penicillin, erythromycin and clindamycin, 
substances that are not expected to have an acceptable effect on E. coli 
infections. 
 
 Staphylococci 
In Sweden, resistance due to beta-lactamase production has during the last 14 
years been recorded in between 75 and 90% of studied canine S. 
pseudintermedius isolates (SWEDRES-SVARM, 2013). Susceptibility to 
penicillin and ampicillin was, as expected due to beta-lactamase production, 
also uncommon in staphylococci in the investigated UTI and SSI. Only 10-
20% of S. pseudintermedius, 20-30% of S. aureus isolates and 15% of the S. 
schleiferi coagulans isolates were susceptible.  
For staphylococci in study I, susceptibility to amoxicillin-clavulanic acid 
was determined according to CLSI breakpoints for treatment of UTI, and 
susceptibility was high; 97-100%. For the SSI isolates, the CLSI BPs for this 
antimicrobial were outside of the concentration ranges of the test panels used. 
However, as the staphylococci were resistant to penicillin and ampicillin 
through beta-lactamase production, amoxicillin-clavulanic acid would most 
likely be a relevant antimicrobial for the isolates susceptible to cephalothin; 
96% of the S. pseudintermedius isolates, 100% of the S. aureus and S. 
schleiferi coagulans isolates, respectively. Furthermore, an almost identical 
percentage of susceptibility to cephalothin was seen in staphylococcal isolates 
from the investigated SSI; 97% of the S. pseudintermedius isolates and 100% 
of the S. aureus isolates. 
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Although CLSI BPs for clindamycin were outside of concentration ranges 
of the test panels used for the SSI cases, erythromycin susceptibility was 77%, 
100 % and 71 % for S. pseudintermedius, S. aureus and S. schleiferi 
respectively, indicating a similar proportion of clindamycin susceptible 
isolates, as discussed above. 
Susceptibility rates to tetracycline were compared to the other 
antimicrobials tested lower; 67-75% in S. pseudintermedius isolates. 
All staphylococcal isolates cultured from UTI cases were susceptible to 
nitrofurantoin. 
 
 Beta-haemolytic streptococci 
Beta-haemolytic streptococci were uniformly susceptible to penicillin. They 
are thereby also considered susceptible to ampicillin (Giguère et al., 2006). 
The isolates were also uniformly susceptible to amoxicillin-clavulanic acid, 
and to trimethoprim-sulphametoxazole. Furthermore, the susceptibility rate to 
nitrofurantoin was 96-100%. 
CLSI BPs were outside of concentration ranges of the test panels used for 
clindamycin. However, only one isolate had clindamycin MICs above the BP 
for resistance, and the MIC90 values were calculated for the isolates from SSI. 
These results indicate that most isolates in study II were susceptible to 
clindamycin. 
The proportion of isolates susceptible to tetracycline was 64-66% and the 
inherently low susceptibility to enrofloxacin was reflected in the results, as 
only 15% of isolates were susceptible. 
 
 Enterococci 
More than 80% of all enterococci were susceptible to ampicillin, amoxicillin-
clavulanic acid, trimethoprim-sulphametoxazole and nitrofurantoin. In 
addition, approximately half of the isolates were susceptible to enrofloxacin.  
The low susceptibility (30%) to the tested cephalosporin was expected, as 
enterococci express low-affinity penicillin-binding proteins (Kristich et al., 
2014). 
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4.3 Carriage of methicillin-resistant Staphylococcus 
pseudintermedius 
 
4.3.1 Length of MRSP carriage 
The repeated sampling of the 31 dogs enrolled in study III showed that dogs, 
after having had a clinically evident infection caused by MRSP, can carry the 
bacteria for several months without clinical signs. Conversely, some dogs were 
found to become MRSP negative within a year.  
The overall median length of MRSP carriage in study III was 11 months. 
Five of the 21 dogs were shown to be MRSP positive for more than 14 months. 
Nine dogs were sampled for 5-12 months and remained positive. One of these 
dogs had a negative result on one sample occasion followed by positive results. 
Fifteen dogs were negative within 12 months and they remained negative 3.5 to 
7.5 months later. Two dogs left the study at five and ten months, respectively, 
with negative results from all sample sites at the final sample occasion.  
Twelve of the fifteen dogs in study III that were sampled until two 
consecutive negative results were achieved were found to be MRSP negative 
within nine months from the time of the inclusion sample, the remaining three 
within twelve months. Four of these dogs were MRSP negative on their very 
first sample occasion. According to the four dogs’ medical charts, the inclusion 
sample was the first bacteriological sampling made in connection with the 
relevant diagnosis, and it is possible that the finding of MRSP in the inclusion 
sample of these dogs was a transient contamination.  
Long-term carriage was also detected in study IV. Two of four dogs in 
study IV were MRSP positive when sampled for carriage four months after the 
inclusion sample, but negative on the next sampling occasion at 10 and 11 
months. A third dog was still positive after 13 months.  
It is possible that MRSP carriage in dogs is not always detectable. If so, a 
previously MRSP positive, then declared MRSP negative dog might become 
culture-positive again, for example due to positive selection of systemic 
antimicrobial treatment to which the bacteria is resistant. As guidelines 
regarding the possibility of declaring a dog as no longer carrying MRSP are 
lacking, a definition of probable MRSP negativity had to be decided prior to 
study III. Length of MRSP carriage was defined as time from the inclusion 
sample until the first of two consecutive negative sample occasions, with the 
exception of two dogs that were found to be negative on only one sample 
occasion, after which they left the study. These two dogs were regarded as 
MRSP negative on that last sample occasion. 
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Although the median time of carriage (11 months) in study III is useful for 
example when comparing results with future studies, it should be remembered 
that the exact length of carriage is difficult to determine. It is unknown if, and 
if so for how long, dogs were already carrying MRSP before the inclusion 
sample. Furthermore the period between sample occasions varied depending on 
when the dogs were available for sampling.  
Intermittent carriage with reinfection of the sampled dogs cannot be ruled 
out. In addition to contact with other MRSP colonized dogs, humans and a 
contaminated environment might serve as a source of infection and reinfection 
(van Duijkeren et al., 2011b, Laarhoven et al., 2011). As the dogs were 
sampled at a veterinary clinic or hospital, there was also an opportunity for 
transmission of MRSP via contaminated environment or staff (Bergstrom et 
al., 2012, Gronthal et al., 2014, van Duijkeren et al., 2011b).  
The samples in study III and IV were with few exceptions, including the 
index samples, not from a clinically infected site. Compared to many common 
bacterial samples from an infected body site, an increased risk of not being 
able to detect the bacteria of interest due to overgrowth of other bacteria and 
fungi might be present when sampling a carriage site. Furthermore, a low 
bacterial count could be a potential problem. 
There were only two exceptions from consistently MRSP positive culture 
results from the sampled dogs. This indicates a low risk of false-negative 
results due to handling of samples and laboratory methods. In study III one of 
27 dogs with at least one positive MRSP culture (index samples excluded) was 
negative on one sample occasion, but positive on the next. In study IV, the 
number was one of four contact dogs, and none of the four index dogs. Other 
longitudinal studies of MRSP in dogs have also noted such exceptions from 
consistently MRSP positive culture results (Bergstrom et al., 2012, Laarhoven 
et al., 2011).  
A selective enrichment broth and a selective agar were used in both study 
III and IV to reduce the possibility of a false negative culture result (Laarhoven 
et al., 2011, Weese and van Duijkeren, 2010, van Duijkeren et al., 2011a). 
Multiple body sites were sampled to increase detection sensitivity (Weese and 
van Duijkeren, 2010, Laarhoven et al., 2011, Rubin and Chirino-Trejo, 2011). 
As a written description of standardised sample methods was sent to the 
veterinarians sampling the dogs, and due to the nature of the sampling, the 
standardisation could be expected to be easy to follow with one possible 
exception. In study III, where the nose was included as a sample site, several 
veterinarians found the nostrils to be more difficult to sample correctly than the 
other sample sites. 
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4.3.2 Investigation of factors that might influence length of MRSP carriage  
Systemic treatment for three weeks or longer with antimicrobials to which the 
bacterium was resistant was in study III associated with prolonged carriage 
compared to shorter treatment periods. Three of five dogs treated with an 
antimicrobial to which their MRSP isolates were susceptible (tetracycline) 
were still MRSP positive after the end of treatment. No significant difference 
was found in study III between length of carriage and diagnosis at time of 
inclusion (dermatitis, surgical procedures or infection/trauma), age (≤ 6 years 
or older), gender (male or female), presence of wounds or signs of dermatitis 
during the longitudinal sampling. However, the presence of non-purulent 
wounds significantly increased the number of positive sample sites. 
Although further research on the influence of antimicrobial treatment on 
MRSP carriage is warranted, logical hypotheses and biological data support the 
finding that systemic treatment with antimicrobials to which the cultured 
MRSP bacteria were resistant increased the length of detectable MRSP 
carriage. The results can be added to those of published studies that have found 
antimicrobial treatment to be a risk factor for MRSP infection. Dogs receiving 
systemic treatment with antimicrobials to which the bacterium is resistant may 
therefore have a higher risk of carrying, spreading, and developing clinical 
infections with MRSP. The risk for facilitating bacterial growth and thereby 
prolonging clinically apparent infections by prescribing antimicrobials should 
not be overlooked. 
The finding that three of five dogs receiving systemic treatment with an 
antimicrobial to which their cultured MRSP isolates were susceptible remained 
MRSP positive was interpreted as a suggestion of MRSP having established 
itself as a part of the normal microbiota, which would prevent total eradication. 
Later publications have suggested that MRSP could be as well adapted to 
canine skin as MSSP (Lehner et al., 2014, Beck et al., 2012). Lehner and co-
workers also suggested that one of several possible explanations behind their 
lack of proven association between antimicrobial treatment and MRSP 
positivity in dogs could be strain-specific variation (Lehner et al., 2014). 
The finding that neither presence of wounds nor signs of dermatitis 
influenced length of carriage, and that dermatitis was not associated with an 
increased number of positive sample sites is interesting. In human medicine, 
the risk of becoming colonised and carry MRSA on the skin, (and thereby the 
risk of spreading the bacteria to other individuals) has been shown to increase 
with such skin changes (Higaki et al., 1999, Gong et al., 2006). The finding 
that presence of non-purulent wounds increased the number of positive sample 
sites (even when the wound as a sample site was excluded) is also interesting, 
as this could be interpreted as a higher risk of spread of MRSP to the 
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environment and other dogs. The sample size of respective group was however 
relatively small, resulting in a corresponding limitation in statistical power, and 
further studies with larger sample sizes might provide more information. This 
was also the case for another factor that was not shown to influence length of 
carriage: diagnosis at time of inclusion.  
Data on medical treatment, veterinary visits, skin lesions or wounds and 
symptoms of infection including dermatitis, was also collected in study IV. 
However, the relatively small sample size precluded statistical analyses of 
whether presence of any of these factors were associated with difference in 
length of MRSP carriage or number of positive sample sites. 
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4.3.3 MRSP carriage in contact dogs 
Table 4.  Overview of MRSP positive (+) and negative (0) sample results, for 
dogs in the four family groups sampled in study IV, labelled A, B, C and D, 
respectively. Dogs are identified by family group and as index dogs (i for the 
first index dog in a group and ii for the second) or contact dogs (c or cc). Time 
of each sampling is shown in brackets as the number of months after inclusion 
sample. 
Table 4.  
 Sampling 1 Sampling 2 Sampling 3 Sampling 4 
 
Family group A 
Ai + + 0 0 
Aii 0 0 0 0 
Ac 0 0 0 0 
Acc + 0 0 0 
 
Time  of sampling 
 
(1 month) 
 
(4 months) 
 
(11 months) 
 
(12 months) 
 
Family group B 
Bi + + + + 
Bc 0 0 0 0 
Bcc + + 0 + 
 
Time  of sampling 
 
(1 month) 
 
(4 months) 
 
(10 months) 
 
(13 months) 
 
Family group C 
Ci + + 0 0 
Cc + 0 0 0 
 
Time  of sampling 
 
(1 month) 
 
(4 months) 
 
(10 months) 
 
(15 months) 
 
Family group D 
Di + + 0 Not sampled 
Dc + + 0 Not sampled 
 
Time  of sampling 
 
(1 month) 
 
(2 months) 
 
(7 months) 
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The results of study IV support that there is a risk of transmission of MRSP 
between dogs living in households where MRSP infection has been diagnosed 
in one of the dogs. This is also reflected in the results of two other studies on 
multidog households (Laarhoven et al., 2011, van Duijkeren et al., 2011b).  
As contact dogs only were found to be MRSP positive in combination with 
MRSP positivity in the index dog on the same sample occasion, the results of 
this study also indicate that the risk of MRSP colonization in dogs living in a 
household together with an MRSP infected dog is lowered if the index dog 
becomes MRSP negative. Furthermore, the finding that three contact dogs 
were consistently negative indicates that not all contact dogs carry MRSP 
continuously while living in a household where MRSP is present. One other 
published longitudinal study involved repeated cultures of contact animals 
within seven households where a dog was known to be MRSP–positive at 
inclusion time (Laarhoven et al., 2011). The authors of that study showed 
similar results in that MRSP positive contact animals generally were only 
found in combination with MRSP positive index dogs, except in one household 
where the index dog became MRSP negative while the contact animal was 
repeatedly MRSP positive. Furthermore, in a one point MRSP prevalence 
study by van Duijkeren and co-workers, contact animals were only MRSP 
positive if the index case showed clinical signs of infection at time of 
sampling, with the exception of one of 20 investigated households (van 
Duijkeren et al., 2011b).  
Further longitudinal studies on MRSP carriage and transmission are 
warranted. However, the findings in study IV support the inclusion of risk of 
transmission of MRSP within multi dog households when developing infection 
control measurements. The possibility of not all contact dogs becoming long-
term carriers should also be taken into account both in further studies on MRSP 
carriage and when recommending restrictions regarding contacts between dogs 
aiming at lowering the risk of further spread of MRSP from an MRSP positive 
household in the community.  
 
4.3.4 Sample site evaluation  
A positive MRSP culture was yielded simultaneously from all the five sample 
sites evaluated in study III (the corner of the mouth, nostrils, pharynx, 
perineum, and when present also wounds) on only 12% of the in total 73 
positive sample occasions. On approximately one third (29%) of the positive 
sample occasions MRSP was yielded from only one of all the sampled sites 
Wound was the sample site with the highest positive MRSP yield in study 
III, with MRSP detected on 81% (n=13) of 16 positive samplings of dogs with 
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wounds present (inclusion samples excluded). The bacteria were isolated from 
pharynx, perineum and the corner of the mouth in 67%, 63% and 58%, 
respectively, of the positive sample occasions.  The nostrils were found to be 
the most difficult site to sample correctly and had the lowest positive yield 
(38%). Whenever the culture from the nostrils was MRSP positive, MRSP 
could also be found in one or more of the other sites. 
The results show that simultaneous sampling of several body sites when 
screening clinically healthy dogs for MRSP should be recommended. A 
minimum of both a nasal and rectal or perineal swabs has previously been 
recommended for both MRSP and MSSP screening (Rubin and Chirino-Trejo, 
2011, Weese and van Duijkeren, 2010). Although wound was the sample site 
with the highest positive MRSP yield, a negative wound culture should not be 
used as a definitive criterion for a dog being MRSP negative, as almost 20% of 
the wound samples were negative despite the bacteria being found in cultures 
from other sites that were sampled simultaneously.  
The results suggest that the nostrils are not a priority when screening dogs 
for MRSP. Others have also suggested that, in contrast to S. aureus in humans, 
where nasal swabs are routinely used for screening purposes, canine carriers of 
S. pseudintermedius can most reliably be identified by swabbing both the oral 
mucosa and the perineum (Bannoehr and Guardabassi, 2012).  
In study IV, the three sample sites used (wounds when present, perineum, 
and a pooled sample from pharynx and the corner of the mouth), were chosen 
based on the results from study III as well as on results from previous 
publications.  Although there were relatively few MRSP positive dogs in study 
IV, the results supported the use of multiple sample sites. Notably more than 
one body site yielded a positive MRSP culture on only two of the fifteen 
positive sample occasions. Wound again had the highest MRSP positive yield: 
71% (n=4) of the seven positive sample occasions where wound were present. 
Approximately half of the MRSP positive cultures, (45%; n=9) were from 
perineum. A third (30%; n=6) were from pharynx and the corner of the mouth.  
 
 
4.3.5 Summary and possible sample strategies for detecting MRSP carriage  
For strategic sampling for asymptomatic MRSP carriage, the recommended 
time for the first sample occasion could be shortly after either end of clinical 
signs of infection or the first MRSP positive carrier sample, to exclude 
contamination. If as few sample occasions as possible are important for 
financial reasons, a repeated sample after a period of at least nine months, 
preferably a year can be recommended. The owner needs to be informed of a 
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possible risk of MRSP not being detected, as well as that a previously declared 
MRSP negative dog might become culture-positive again. 
The results suggest that simultaneous sampling of pharynx, perineum and 
the corner of the mouth, as well as wounds when present, should be 
recommended, and that sampling of nostrils is not a priority when screening 
dogs for MRSP. 
Temporarily relocating contact dogs from a household where an MRSP 
infected dog has been detected might render repeated MRSP negative results in 
a shorter time period, compared to if the dogs had stayed together with the 
index case. Removing an MRSP positive dog temporarily from the household 
to avoid transmission to other pets has previously been suggested as a possible 
intervention (van Duijkeren et al., 2011b, van Duijkeren et al., 2011a). Other 
suggested preventative measures include bathing of the dog as this should 
reduce the contamination of the coat, and cleaning and disinfection of the 
contaminated environment with the aim to reduce the number of organisms 
(van Duijkeren et al., 2011a). Furthermore, proper basic hand hygiene routines 
in persons in contact with dogs have been suggested, with the aim to reduce 
transmission of coagulase-positive bacteria including MRSP between humans 
and pets in the household (Hanselman et al., 2009). 
Systemic treatment with antimicrobials to which the bacterium is resistant 
may increase the risk, and length of, carriage and clinical infection with MRSP. 
Treatment with antimicrobials to which the bacteria is susceptible has not been 
shown to end MRSP carriage (Weese et al., 2012, Beck et al., 2012, Lehner et 
al., 2014, Eckholm et al., 2013, Windahl et al., 2012). Systemic antimicrobial 
treatment in dogs with possible or confirmed MRSP carriage or infection 
should therefore be avoided when possible.  
It is possible that MRSP is emerging as more of a healthcare associated 
pathogen than a community associated pathogen. Veterinary hospitals and 
practices may play an important, or even central role in the dissemination of 
MRSP. When colonized and infected patients due to HAI become more 
prevalent in the community, the risk of community-acquired MRSP in turn 
increases. Preventative measures towards spread of MRSP in veterinary 
healthcare facilities should therefore be considered to be a cornerstone in 
combating the increase of this multidrug resistant bacterium (van Duijkeren et 
al., 2011a, Bergstrom et al., 2012, Wieler et al., 2011b). 
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5 Conclusions 
 
 Escherichia coli was the most frequent pathogen in the investigated UTI, 
identified in approximately 70% of the cases. Staphylococcus 
pseudintermedius and S. aureus were more prevalent in pre-incubated 
samples than in non-incubated samples.  
 
 Approximately two-thirds of all isolates identified in the investigated SSI 
were staphylococci. Staphylococcus pseudintermedius was the most 
frequent pathogen identified (46% of isolates). There were no associations 
between relative presence of bacterial species and category of surgical 
procedure (clean, clean-contaminated, contaminated or dirty). 
 
 An MDR pathogen was detected in 4% of all UTI and in 19% of all SSI. 
Three percent of detected E. coli isolates were ESC-resistant. Less than 3% 
of S. pseudintermedius isolates were methicillin resistant. No MRSA 
isolates were found.  
 
 First-line antimicrobials were found to be a rational empirical antimicrobial 
therapy for the studied dog population. Excluding the MDR infections 
where still at least one relevant antimicrobial was available, there were 
several relevant first-line treatment options in all the investigated UTI and 
SSI.  
 
 Dogs carried MRSP for several months without clinical signs. Systemic 
treatment for three weeks or longer with antimicrobials to which the 
bacterium was resistant was associated with prolonged carriage compared 
to shorter treatment periods. Three of five dogs treated with an 
antimicrobial to which the MRSP isolates were susceptible remained MRSP 
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carriers. These findings support restricted use of systemic antimicrobial 
treatment in dogs with possible or confirmed MRSP carriage or infection. 
 
 The risk of MRSP colonization in dogs living in a household with an MRSP 
infected dog might be lowered if the clinically infected dog (index dog) 
becomes MRSP negative. Furthermore, all contact dogs in the family might 
not carry MRSP continuously during the time the index dog is MRSP 
positive. 
 
 The results of the evaluation of five body sites for MRSP carriage screening 
suggest that simultaneous sampling of pharynx, perineum and the corner of 
the mouth, as well as wounds when present, should be recommended. 
Furthermore, the results suggest that sampling of nostrils is not a priority 
when screening dogs for MRSP.  
 
 For strategic sampling for asymptomatic MRSP carriage, the recommended 
time of first sample occasion could be shortly after either end of clinical 
signs of infection or the first MRSP positive carrier sample, to exclude 
contamination. If as few sample occasions as possible are important for 
financial reasons, a repeated sample after a period of at least nine months, 
preferably a year can be recommended. 
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6 Future perspectives 
Several research- and knowledge gaps are readily identified. A few examples 
are listed below. 
Neither the true prevalence of zoonotic MDR bacteria in dog populations, 
nor the actual zoonotic risk is well described. Further research into 
transmission of MRSP, Enterobacteriaceae with ESC-resistance and other 
potentially MDR bacteria between dogs, as well as between dogs and humans 
is needed.  
Published surveillance reports on antimicrobial resistance in dogs are 
currently few, and much baseline data on antimicrobial susceptibility needed 
for clinical therapy decisions, as well as for development of policy 
recommendations for companion animals, is lacking. An increased 
internationally coordinated surveillance of antimicrobial resistance in canine 
bacteria would be beneficial, also to permit the early detection of resistant 
strains and support investigation of outbreaks. Importantly, such surveillance 
should include not only cultures from patients that are “worst case scenarios”, 
but a broad, representative population so that the actual levels of antimicrobial 
resistance are reflected. Relative bacterial growth, and susceptibility patterns in 
specified infections such as UTI and SSI, should be presented so that studies 
and reports can be compared. Such reports also aid in evaluation of in-house 
surveillance schemes at individual animal hospitals and clinics, including 
recognizing diverging results so that appropriate measures are instigated. 
Preventive measures against infections in both individual animals and 
broader animal populations that influence animal health and/or public health 
should be a priority in veterinary medicine. Surprisingly little attention has in 
the world of dog breeding been directed towards the possibility of breeding 
dogs that are less prone to skin disease and secondary bacterial skin infections 
including pyoderma. An increase in research directed towards how to breed 
dogs less at risk for developing such bacterial infections is warranted.  
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Further research is needed in the area of underlying factors for bacterial 
disease, included pathogenic mechanisms of key pathogens such as S. 
pseudintermedius and MRSP. Development of effective vaccines and other 
evidence based preventative strategies, including more veterinary-specific 
products aimed at treatment of key infections and key pathogens would be 
most welcome in small-animal medicine 
Based on current knowledge, relevant measures in reducing spread of 
bacteria in the dog population include health care infection control and rational 
antimicrobial use. However, much more knowledge is needed, including in the 
area of community-associated epidemiology. Veterinarians as well as dog 
owners only have a limited amount of research-based information when 
deciding whether a dog, or a group of dogs, should be considered high- or low-
risk individuals regarding transmission of bacteria to other dogs, or to humans. 
Further knowledge is also needed on what interventions should be prioritized, 
and how the effect of such interventions should be measured. Further 
longitudinal studies of carriage of MRSP and MRSA are clearly warranted. 
The potentially potent role of dogs as part of planned treatment strategies in 
human healthcare has recently been increasingly acknowledged. Research 
based guidelines on how to best prevent possible risks for zoonotic bacterial 
carriage or infections due to such human-pet interactions is much needed. 
Furthermore, the possible role of dogs in transmission and outbreaks of 
infections with various zoonotic bacteria to and from food producing animals is 
poorly investigated. 
Increasing knowledge and awareness of the value of diagnostic 
investigation, and prudent antimicrobial use is needed both in the veterinary 
field and the general public. Widely, easy accessible research-based best 
practice manuals, including information directed at the animal-owners could 
support attending veterinarians when trying to change old patterns in use of 
antimicrobials. An increased knowledge and awareness of the value of 
implementing proper infection control, and on how to establish infection 
control programs is needed in the veterinary community. 
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7 Populärvetenskaplig sammanfattning 
En ökad förekomst av antibiotikaresistenta bakterier hos hund rapporteras från 
hela världen. Både den behandlande veterinären och djurägaren ställs i och 
med detta idag allt oftare inför svåra val. Infektioner som tidigare 
framgångsrikt kunde behandlas med antibiotika kan idag leda till att hunden 
avlivas. Antibiotikabehandling med antibiotika som bakterien är resistent mot 
kan ge förvärrade infektionssymtom.  
Utdragna infektionsförlopp leder till ett ökat lidande för den enskilda 
hunden. Varje enskild infektion med resistenta bakterier kan också innebära en 
risk för ytterligare spridning av bakterien eller resistensen. Bakterier med ESC-
resistens (resistens mot extended-spectrum cephalosporins), MRSA (meticillin-
resistenta Staphylococcus aureus), samt MRSP (meticillin-resistenta 
Staphylococcus pseudintermedius), är exempel på särskilt problematiska 
infektioner. ESC-resistens kan spridas inte bara genom smitta av resistenta 
bakterier mellan människor, människa-hund och hundar, utan också genom att 
de gener som bär på resistensen överförs mellan olika bakteriearter.  MRSA 
infektioner har hittills varit mycket ovanliga hos hund jämfört med hos 
människa, där den i många länder orsakar stora problem. 
Bakterien Staphylococcus pseudintermedius (S. pseudintermedius) är en del 
av hundens normala bakterieflora, men samtidigt också den i särklass 
viktigaste och vanligaste orsaken till bakteriella infektioner hos hund. Sällsynta 
fall av infektion hos andra djur, och hos människa  med denna bakterie har 
rapporterats, men anses vara ovanliga. År 2005 uppmäksammades de första 
fallen i Europa av en multiresistent variant av denna bakterie, MRSP. MRSP 
infektioner hos svenska hundar har som regel varit resistenta mot samtliga 
antibiotika i tablett- och injektionsform registrerade för hund, med ett 
undantag: tetracyklin. En del infektioner har även varit resistenta mot detta 
antibiotikum.  
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En snabb ökning av antalet MRSP fall har samtidigt påvisats i både Europa 
och Nordamerika. Mycket kunskap som behövs för att ta fram relevanta 
åtgärdsplaner mot fortsatt spridning, och för hur man bör provta hundar som 
kanske kan sprida smittan utan att de själva har symtom saknas. 
I de två första studierna i denna av handling undersöktes bakterier som 
orsakade urinvägsinfektioner och infektioner i operationssår, och vilka 
antibiotika de var resistenta mot. Escherichia coli (E. coli) var den vanligaste 
bakterien i urinvägsinfektionerna. Den allra vanligaste bakterien i 
sårinfektionerna var S. pseudintermedius, som påvisades i nära hälften (46 %) 
av alla sårinfektioner. Tillsammans påvisades tre typer av stafylokocker, 
inkluderande S. pseudintermedius, i ungefär 60 % av sårinfektionerna.  
Undersökning av bakterie växten i de olika provmaterial som användes till 
urinproverna visade att stafylokocker kan vara lättare att hitta om den 
provtagande veterinären förodlar provet innan det skickas vidare till ett annat 
laboratorium för vidare undersökning. För sårinfektionerna gick det inte att se 
någon statistisk skillnad mellan vilka bakterier som orsakade infektion och 
vilken typ av operation som hade utförts. 
Jämfört med många internationella rapporter var resistensen överlag låg. 
Äldre rekommendationer avseende förstahandsval av antibiotika till hund var 
fortfarande relevanta. I de allra flest fallen fanns ett flertal antibiotika 
registrerade för hund att välja på, och det fanns aldrig något behov av att 
använda två antibiotika samtidigt, eller antibiotika avsedda att i första hand 
användas till allvarliga infektioner hos människa.  
Multiresistenta bakterier påvisades dock i cirka 4 % av totalt 623 stycken 
urinvägsinfektioner och 19 % av totalt 154 stycken sårinfektioner. I tre 
infektioner påvisades också bakterier med ESC-resistens, vilket för några år 
sedan inte setts hos svenska hundar. I fyra infektioner påvisades MRSP 
bakterier. Inga MRSA infektioner påvisades. 
De två sista studierna inriktade sig på smittspridning av MRSP hos hundar. 
Resultaten visade att hundar kan bära på MRSP utan att visa symtom i över ett 
år, efter att den ursprungliga infektionen (till exempel hudinfektion eller 
sårinfektion) läkt av. Hos en del hundar kunde dock bakterien inte längre hittas 
redan efter några månader. Faktorer som skulle kunna påverka bärarskapets 
längd undersöktes, och behandling med antibiotika som bakterien var resistent 
mot visades förlänga tiden. Fem hundar fick antibiotika om bakterien var 
känslig för. Tre av dessa fortsatta att bära på MRSP. Dessa fynd stödjer 
undvikande av antibiotikabehandling av hundar som kan misstänkas bära på 
MRSP.   
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MRSP kunde inte alltid hittas hos övriga hundar i hushåll med en MRSP 
infekterad hund. Hundarna tenderade att bli MRSP negativa när den 
ursprungligen MRSP infekterade hunden blev negativ. 
Fem provtagningsställen jämfördes, för att kunna ge rekommendationer om 
effektiv provtagning för bärarskap av MRSP. Resultaten visade att flera ställen 
bör provtas för att säkert hitta MRSP. Sår var säkrast, därefter området kring 
analöppningen samt mungipa/svalg.  
Sammantaget rekommenderas att sår eller hudskada, samt både svalg, 
området kring analöppningen och mungipa provtas för MRSP hos symtomfria 
hundar. Första provtagningstillfället kan förläggas en kort tid efter att hunden 
är symtomfri, och om det är positivt upprepas efter nio månader eller längre 
tid, när så få provtagningstillfällen som möjligt önskas. En del hundar i samma 
hushåll som en MRSP infekterad hund kanske kan bli MRSP negativa snabbare 
om de byter miljö och inte träffar den infekterade hunden. Vidare forskning 
behövs dock innan man säkert kan säga hur stor risken är att en hund med 
MRSP negativa prover trots detta kan visa sig vara MRSP positiv en tid senare, 
till exempel efter en antibiotikabehandling med antibiotika som bakterien är 
resistent mot. 
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